Stockwinners Market Radar for September 30, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EDT Viridian Therapeutics CEO buys $499.3K in common stock - In a regulatory filing, Viridian Therapeutics disclosed that its CEO Stephen Mahoney bought 21.4K shares of common stock on September 27th in a total transaction size of $499.3M. Viridian Therapeutics shares ended after-hours session up 4% at $23.63.

20:02 EDT Cathie Wood's ARK Investment buys 74K shares of Blade Air Mobility today

19:50 EDT BrainStorm trading halted, news pending

18:32 EDT Kura Oncology announces Ziftomenib Phase 1 results in The Lancet - Kura Oncology "announced the publication of its KOMET-001 Phase 1 study manuscript in The Lancet Oncology journal. The paper, entitled "Ziftomenib in relapsed/refractory acute myeloid leukaemia: results from an open-label, multi-cohort, phase 1a/1b trial," is now available on The Lancet Oncology website and in the Scientific Manuscripts section on Kura's website. The KOMET-001 study is a Phase 1/2 global, open-label, multi-cohort clinical trial evaluating the safety, tolerability and clinical activity of ziftomenib in relapsed/refractory AML. In the Phase 1a dose escalation portion, patients received ziftomenib once daily in 28-day cycles and in the Phase 1b dose validation/expansion portion, patients were randomized to two parallel cohorts at 200 mg and 600 mg. As of the data cutoff on August 30, 2023, 83 patients received one or more doses of ziftomenib and the primary objective of this study was to determine the recommended phase 2 dose based on safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity. The results demonstrated promising clinical activity with manageable toxicity in heavily pretreated patients including marrow blast reduction, neutrophil and platelet recovery, transfusion independence, and clearance of measurable residual disease. In May 2024, Kura Oncology announced completion of enrollment in the Phase 2 portion of KOMET-001, a registration-directed trial of ziftomenib in patients with R/R NPM1-mutant AML. Enrollment of the 85 patients in Phase 2 was completed in fewer than 16 months and the Company expects to report topline data from the trial in early 2025."

17:41 EDT Micron CPO Arnzen sells 4,890 common shares - In a regulatory filing, Micron chief people officer April Arnzen disclosed the sale of 4,890 common shares of the company on September 26 at a price of $113 per share.

17:32 EDT Lockheed Martin awarded $321.62M Missile Defense Agency contract - Lockheed Martin was awarded a modification in the amount of $321.62M to provide additional scope on their existing sole-source, hybrid, cost-plus-incentive-fee and cost contract for Aegis BMD Weapon Systems. This modification increases the ceiling of Contract L ine-Item Numbers 4005, 4007, 4008, and 4009 to support BMD 6.0.1 development scope. Work will be performed in Moorestown, New Jersey, with a performance period from October through June 2025. An initial obligation in the amount of $14.19M using fiscal 2024 research, development, test and evaluation funds will occur at the time of award. The value of the contract will increase from $25.56Mto $347.18M. The Missile Defense Agency is the contracting activity.

17:28 EDT Lockheed Martin awarded $348.46M Navy contract order - Lockheed Martin was awarded a not-to-exceed $348.46M undefinitized, cost-plus-fixed-fee order against a previously issued basic ordering agreement. This contract procures initial air vehicle spares for the production Lot 18 aircraft to include basic spares pool/global spares pool spares shared between the involved customers, customer specific afloat spares pool/deployable spares pool as well as associated support and consumables to meet immediate maintenance needs of the Joint Strike Fighter Program for the Navy, Air Force, Marine Corp, Foreign Military Sales customers, and non-U.S. Department of Defense participants. Work is expected to be completed in October 2029. Naval Air Systems Command is the contracting activity.

17:23 EDT Lockheed Martin awarded $1.17B Navy contract - Lockheed Martin was awarded a $1.17B hybrid cost plus incentive fee and cost-plus fixed fee contract, to provide Strategic Weapon System Trident fleet support, Trident II shipboard integration increment eight, and navigation subsystem development efforts. This contract award also benefits a foreign military sale to the United Kingdom. Work is expected to be completed by September 29, 2031. This contract is being awarded subject to the availability of Fiscal 2025 funds and no funds will expire at the end of the current fiscal year. This contract is being awarded as a sole-source pursuant to 10 U.S. Code 3204(a)(1) and (4). Strategic Systems Programs is the contracting activity.

17:20 EDT Lockheed Martin awarded $2.11B Navy contract modification - Lockheed Martin was awarded a $2.11B hybrid fixed-price-incentive-fee, cost-plus-incentive-fee, and cost-plus-fixed-fee modification to a previously awarded and announced un-priced letter contract for Trident II D5 missile production and deployed systems support and Warhead 93/Mark7 development. This contract award also benefits a Foreign Military Sale to the United Kingdom. Work is expected to be completed September 30, 2029. FY24 weapons procurement funds in the amount of $143.46M will be obligated on this award and no funds will expire at the end of the current fiscal year. The maximum dollar value of the contract action, including all Optional Line Items if exercised, is $2.11B. This contract is being awarded to the Contractor on a sole source basis under 10 U.S. Code 2304(a)(1) and was previously synopsized on the Systems for Award Management website, with one proposal received. Strategic Systems Programs is the contracting activity.

17:17 EDT Boeing awarded $600M Air Force contract - Boeing was awarded a $600M indefinite-delivery/indefinite quantity contract for Joint Direct Attack Munition and Laser Joint Direct Attack Munition testing and integration. This contract provides for technical services and support, aircraft and weapon system integration, and sustainment. Work is expected to be completed by September 29, 2035. This contract involves Foreign Military Sales to Israel, Singapore, Philippines, Indonesia and Turkey. This contract was a sole source acquisition. Fiscal 2024 procurement funds in the amount of $3.6M are being obligated at the time of award. The Air Force Lifecycle is the contracting activity.

17:13 EDT Boeing awarded $6.9B Air Force contract action - Boeing was awarded a ceiling $6.9B undefinitized contract action, fixed-price incentive, indefinite-delivery/indefinite-quantity contract for Small Diameter Bombs Increment One. This contract provides for Lots 20-29 production and delivery of Small Diameter Bombs, and a guaranteed minimum Lot 20 award. Work will be performed in St. Louis, Missouri, and is expected to be completed by December 31, 2035. This contract involves Foreign Military Sales to Japan, Bulgaria, and Ukraine. The Direct Attack Guidance Branch is the contracting activity.

16:57 EDT Target's Gomez sells 6,348 common shares - In a regulatory filing, Target executive officer Richard Gomez disclosed the sale of 6,348 common shares of the company on September 27 at a price of $157.17 per share.

16:52 EDT Life Time Group closes two sale-leaseback transactions - Life Time Group "announced that it has closed on two sale-leaseback transactions for two properties for approximately $65 million in gross proceeds. Terms were similar to recent transactions. These transactions bring the Company's total gross proceeds from sale-leasebacks to approximately $213 million year-to-date."

16:37 EDT Walmart CEO McMillon sells 29,124 common shares - In a regulatory filing, Walmart president and CEO Douglas McMillon disclosed the sale of 29,124 common shares of the company on September 26 at a price of $80.6426 per share.

16:36 EDT Trump Media expands TV streaming delivery network - Trump Media announced that its custom-built content delivery network, or CDN, is now operating from multiple sites across the country. The company said that the expansion transforms Truth Social's CDN-which powers the company's Truth+ TV streaming service-into a more sophisticated distributed content network, with streaming content originating from multiple geographic locations.

16:30 EDT Gritstone announces interim GRANITE study data - Gritstone announced interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer, or MSS-CRC. The randomized, controlled study is designed to evaluate the clinical benefit of maintenance therapy with GRANITE in combination with immune checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone. Overall progression-free survival data show an encouraging benefit for GRANITE patients. As expected, the greatest benefit was observed in the 50% of patients with lower disease burden at study entry, as measured by circulating tumor DNA at study baseline. Continued follow-up is needed to fully assess GRANITE effects and determine whether a plateau of improved PFS is achieved. The most recent ctDNA assessments for the 20 patients who remain without disease progression were supportive of potential benefit from treatment with GRANITE: 12 of 13 GRANITE patients had stable ctDNA titers below the assay limit of quantitation; 4 of 7 control patients exhibited the same characteristic. Interim data demonstrated an emerging PFS benefit to all GRANITE recipients 21% relative risk reduction of progression or death with GRANITE vs. standard of care control in all treated population 33% GRANITE and 23% of control patients remain on study and free of progression. Last ctDNA assessment is below the assay LOQ in 12/13 GRANITE and 4/7 control patients. Clinical benefit was most notable in patients with low disease burden. 38% relative risk reduction of progression or death with GRANITE vs. SOC control with low ctDNA subgroup. Low baseline ctDNA is a likely prognostic and predictive factor. Immune data were consistent with clinical activity. Functional neoantigen-specific T cells were observed in all 16/16 GRANITE patients tested by ELISPOT. Association of PFS and peak ex vivo ELISPOT responses was apparent, suggesting that ex vivo ELISPOT may be a surrogate for PFS. GRANITE demonstrated a favorable safety and tolerability profile. No patients discontinued study treatment due to an adverse event. Common adverse events were the mild systemic and local effects associated with any potent vaccine, i.e. transient flu-like illness. One treatment-related serious AE occurred in the GRANITE arm. Gritstone plans to review the PFS data with FDA in the coming months and agree on next steps to advance GRANITE, including a potential Phase 2 or 3 trial using ctDNA levels as eligibility criteria.

16:26 EDT MDU Resources appoints Anthony Foti Chief Legal Officer - MDU Resources Group board of directors has approved the appointment of Anthony Foti as Chief Legal Officer and corporate secretary, effective October 7. He will report directly to MDU Resources president and CEO, Nicole Kivisto, and succeed Paul Sanderson, who was previously announced as VP, Chief Legal Officer and secretary at Everus Construction Group.

16:22 EDT Zscaler announces Adam Geller as chief product officer - Zscaler announced the appointment of Adam Geller as chief product officer to scale and accelerate the company's next phase of innovation and growth. Geller has over 25 years of product and engineering experience across multiple domains of cybersecurity.

16:20 EDT Nasdaq notifies AmpliTech Group of non-compliance of listing rules - AmpliTech Group eceived a notice from The NASDAQ Stock Market indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under the Nasdaq Listing Rules . Based on the closing bid price of the Company's listed securities for the last 30 consecutive business days from August 15, 2024 to September 26 the Company no longer meets the minimum bid price requirement set forth in Listing Rules 5550(a)(2). The Notice is only a notification of deficiency and has no current effect on the listing or trading of the Company's securities on The Nasdaq Capital Market...The Company intends to monitor the closing bid price of its common stock between now and March 26 and to evaluate its available options to regain compliance within the compliance period.

16:18 EDT CTO Realty Growth reports $275M of investment activity year-to-date - The Company's investment activity, including acquisitions and structured investments, was $191.3M in the quarter and now totals $273.8M year-to-date, at a weighted average yield of 9.1%. As the Company has exceeded its 2024 guidance for investment activity, it will provide updated investment guidance when reporting its full third quarter results on October 24. In addition to previously announced investment activity, the company recently originated a $43.8M first mortgage loan that has an initial term of two years with a one-year extension option, carries an initial fixed interest rate of 11%, and included an origination fee of 1.25%. The loan is secured by over 100 acres entitled for an over 2 million square foot mixed-use development

16:16 EDT Trinseo announces restructuring moves, will exit virgin polycarbonate output - Trinseo announced restructuring initiatives to better position the business for longer-term growth, improved profitability, and increased cash generation. Effective October 1, 2024, the Company is combining the management of its Engineered Materials, Plastics Solutions and Polystyrene businesses, resulting in a reduction in workforce due to the consolidation of business management roles and support functions. These actions began in the third quarter of 2024 and are anticipated to be substantially complete by the end of 2025. The expected annualized run rate cost savings is $30 million with approximately $25 million realized in 2025 and the full run rate achieved by the end of 2026. The newly combined Engineered Materials, Plastics Solutions and Polystyrene businesses will be led by Francesca Reverberi, SVP, Engineered Materials. Bregje "Bee" Van Kessel, who currently leads the Plastics Solutions and Polystyrene businesses, will assume the role of SVP, Corporate Finance and Investor Relations reporting to David Stasse, EVP, Chief Financial Officer. Han Hendriks, who leads technology and innovation, will add oversight responsibilities for the Company's sustainability activities as Chief Technology and Sustainability Officer. Additionally, the Company has decided to exit virgin polycarbonate production at its Stade, Germany production facility following discussions with the relevant works councils. Production is anticipated to end by January 2025 with severance and related benefit payments expected to complete by the end of 2026. Once operations have ceased, all the Company's polycarbonate needs for its downstream, differentiated compounded products will be purchased from external suppliers, including its licensees, with the exception of its dissolution-based polycarbonate production. This purchasing change is expected to result in an annualized run rate profitability improvement of $15 million to $20 million relative to manufacturing at Stade. The Company expects to record total pre-tax restructuring charges of $23 million to $28 million, principally comprised of $22 million to $26 million of severance and related benefit costs and $1 million to $2 million of asset-related and contract termination charges, primarily related to the virgin polycarbonate manufacturing site in Stade, Germany.

16:10 EDT IGM Biosciences CEO Fred Schwarzer, CSO Bruce Keyt, CMO Chris Takimoto step down - As part of the company's strategic pivot to autoimmunity, Fred Schwarzer, CEO, president and director, and Bruce Keyt, chief scientific officer, or CSO, will step down from their current roles at the company. Schwarzer and Keyt are expected to remain as consultants. Chris Takimoto, chief medical officer, is stepping down from his current role to pursue an opportunity outside the company.

16:06 EDT Repare Therapeutics reports 'encouraging' Phase 1 camonsertib combo data - Repare Therapeutics reported data highlighting the clinical benefits of camonsertib, a potential best-in-class oral small molecule ATR inhibitor, combined with palliative radiation for the treatment of metastatic tumors harboring an ataxia-telangiectasia-mutated mutation. These data from a clinical trial conducted in collaboration with investigators at Memorial-Sloan Kettering Cancer Center were presented at the American Society for Radiation Oncology annual meeting in Washington, DC by Nancy Lee, MD, FASTRO, Radiation Oncologist & Early Drug Development Specialist, Memorial Sloan Kettering Cancer Center and titled, "Genotypically-Selected Pan Cancer Trial of Camonsertib with Palliative Radiation in the Treatment of Metastatic Tumors Harboring an Ataxia-Telangiectasia Mutated Mutation." "These encouraging early Phase 1 data build further support for the broad clinical potential of camonsertib," said Maria Koehler, MD, PhD, Executive Vice President and Chief Medical Officer of Repare. "This first-in-human study combining camonsertib, an ATR inhibitor, with palliative radiation provides early clinical data showing that the combination has the potential to radiosensitize for higher clinical benefit in patients with tumors harboring pathogenic ATM mutations versus those with variants of unknown significance. We are highly encouraged by this early look at the response rate and safety profile of this combination in the Phase 1 setting."

16:06 EDT Genius Sports names Mark Kropf group CTO - Genius Sports Limited (GENI) announced the appointment of Mark Kropf as its Group Chief Technology Officer. Kropf joins Genius Sports from Google (GOOGL), where he held the position of Technical Director within Google's Office of the Chief Technology Officer. In this role, Kropf played an instrumental role in advancing Google's generative AI capabilities, improving developer experience and driving sustained innovation. Mark Locke, CEO of Genius Sports, said: "I am thrilled to welcome Mark Kropf as our Group CTO. His outstanding track-record of technology leadership at both Google and Pivotal, combined with his deep experience in AI-focused innovation, will play a critical role in our future. Our cutting-edge GeniusIQ platform is already driving the AI revolution in the global sports ecosystem and Mark's expertise will play a key role in amplifying and accelerating that transformation."

16:01 EDT Quanterix announces commercialization of p-Tau 217 test kit - Quanterix (QTRX) "announced it is making its Simoa(R) p-Tau 217 Planar Kit commercially available as part of the next phase of Alzheimer's Disease test development. The kit uses p-Tau 217 antibody technology licensed from Eli Lilly and Company (LLY) and Quanterix's SP-X platform. In March 2022, Quanterix first announced its entry into license and collaboration agreements with Lilly, which specified the initial development of a test for the Eli Lilly Clinical Diagnostics Laboratory, a wholly owned subsidiary of Lilly. Now, with the Simoa(R) p-Tau 217 Planar Kit, Quanterix will expand access to this technology by selling customers research use only (RUO) instrumentation and consumables to develop p-Tau 217 blood tests and services using p-Tau 217 antibody technology licensed from Lilly. The Simoa(R) p-Tau 217 Planar Kit will be available immediately."

15:58 EDT Focus Impact Acquisition Corp trading halted, volatility trading pause

14:41 EDT Nauticus completes Aquanaut Mark 2 qualification, begins commercial operations - Nauticus Robotics announced completion of qualification testing of its flagship underwater vehicle, Aquanaut Mark 2. The Aquanaut used for testing, Vehicle 2, is now performing commercial inspection work at a production field in the Gulf of Mexico. This transition from qualification to commercial operations marks a major milestone for the company. Nauticus' Autonomous Solutions team completed the qualification testing at a decommissioned field off the coast of Louisiana. All testing was performed autonomously without need of a tether. Vehicle capabilities now certified are flyover surveys, leak detection, obstacle avoidance, and visual inspections. The team also verified sending mission updates mid-execution using only acoustic communications. The vehicle accepted and changed the mission as commanded. As part of the missions, Aquanaut sent compressed photos to the surface via acoustic communications, which the operators viewed for subsea asset verification. Following the successful testing and data review, Vehicle 2 transitioned to full-scale commercial operations at a nearby production field in approximately 1,000 meters of water.

14:35 EDT CleanSpark says no material damage to any site infrastructure from hurricane - CleanSpark provided comments and updates on the impact of Hurricane Helene, including a statement from CEO Zach Bradford, who said in part: "In the wake of Hurricane Helene's destructive path across the Southeastern United States, we extend our deepest condolences to the communities, families, and individuals who have suffered loss, damage, and disruption due to this catastrophic event. We recognize the immense challenges faced by those in regions where the storm has left countless without power, water, and other basic necessities. The loss of life, including first responders who bravely served during this crisis, underscores the severity of Helene's impact. Our thoughts are with every person whose life has been altered by this hurricane... Most importantly, all our team members are safe. Additionally, our geographically diverse portfolio of sites allowed us to maintain approximately 10.5 EH/s at our sites in Northwest Georgia, Mississippi, and Tennessee throughout the storm. To ensure health and safety, and to avoid any undue pressure on the electrical grid, we shut 365 MW of our Southeast Georgia sites down as the hurricane began impacting the region. Since then, we have been in regular communication with the local utilities to safely bring up the sites in a manner that ensured the local community was supported throughout the process. Within 24 hours, we were able to bring hashrate back to over 17.5 EH/s. We have now brought approximately 200 MW back online and expect to bring the remaining 165 MW online in the coming week after the utilities and communities around us receive power. The majority of the 165 MW remaining offline is projected to be restored to communities no later than October 4, 2024. Our teams are prepared to promptly restore normal operations as soon as power becomes available. We have also thoroughly evaluated all of our sites and are pleased to report that we have experienced no material damage to any site infrastructure. We are not aware of any material losses related to our mining servers and will continue this evaluation as we energize the remaining sites. Our hashrate is currently at approximately 22 EH/s. When our sites are fully reenergized, we expect to reach standard operations at approximately 28 EH/s."

14:18 EDT LVMH sells Off-White LLC to Bluestar Alliance, terms not disclosed - LVMH announced that it has sold Off-White LLC, the company that owns the Off-White brand, to Bluestar Alliance, LLC, a New York-based brand management company. Terms of the transaction are not being disclosed. Founded in 2012 by Virgil Abloh, Off-White is an international luxury streetwear brand. "Virgil was a creative pioneer who had a profound impact on the global fashion industry and creative community. Acquiring Off-White represents a unique opportunity for Bluestar Alliance to honor and build upon the enduring legacy of Virgil Abloh. His visionary approach to fashion resonates deeply with our core values. Abloh's ability to fuse street culture with high fashion has laid a powerful foundation that aligns with our vision of fostering innovation while embracing diversity. The acquisition of Off-White, and the opportunity to provide strategic investment and build upon our global network of resources will allow for the continuation of the cultural and creative momentum that Virgil ignited, one that Bluestar Alliance is committed to carrying forward," said Joey Gabbay, CEO of Bluestar Alliance.

12:22 EDT Ford unveils Ford Power Promise to provide benefits to EV buyers - Ford announced the Ford Power Promise, which is a suite of benefits to customers who purchase or lease a new electric vehicle. "Buy or lease a retail Ford Mustang Mach-E, F-150 Lightning or E-Transit and take a complimentary home charger with you or have it delivered, and when you're ready, an expert comes out to install it at no charge for a standard install," the company said. "This takes the guesswork out of installation, including costs, to help you save time and money by filling up at home. Less stress, more convenience.If you're a Ford Pro fleet customer, we have you covered with a commercial charging cash incentive... Road trips don't happen every day, but when you are on the road, you need to know where to fill up. Our BlueOval Charge Network automatically searches for chargers across various networks, including Electrify America and Tesla Superchargers and adds charging stops to your route via the Connected Navigation in the vehicle. With Plug and Charge, you plug in when you get there, and the payment is automatically made via your FordPass account. It's that easy... We're confident in the quality of our batteries, and we want you to be confident, too. That's why we provide an eight-year/100,000-mile high-voltage battery warranty for every Ford electric vehicle. Ford has your battery covered... We're dedicated to providing you with the support you need whenever you need it, including complimentary roadside assistance if your vehicle's range runs too low. We're also expanding our 24/7 Ford advisor for electric vehicle support, so you'll be talking or texting with real people. We are here when you need us." Reference Link

12:00 EDT Stellantis falls -13.8% - Stellantis is down -13.8%, or -$2.21 to $13.85.

12:00 EDT Heritage Insurance falls -18.1% - Heritage Insurance is down -18.1%, or -$2.81 to $12.70.

12:00 EDT Yirendai rises 13.2% - Yirendai is up 13.2%, or 66c to $5.65.

11:50 EDT Conmed says Hurricane Helene impacted operations in Florida, Georgia - In a regulatory filing on September 30, 2024, CONMED Corporation issued the following statement on the impact from Hurricane Helene on the company's operations: "The path of Hurricane Helene impacted the Company's manufacturing facility in Largo, Florida and the Company's distribution center in Lithia Springs, Georgia. The Company prioritizes the safety of its employees, and ceased manufacturing operations at its Largo, Florida facility for approximately 24 hours. Employee absences at the Largo facility were significant after the storm had passed, temporarily impacting the facility's manufacturing. As of September 30, 2024, the Company has confirmed that all employees are safe, and no significant damage was reported at either facility, and both facilities are back to normal operations. The Company also understands that its customers in the southeastern United States delayed surgeries and other activity due to the storm, and some areas continue to be affected. The Company is unable to estimate the financial impact of Hurricane Helene at this time."

11:10 EDT Hess announces HSR merger clearance, says John Hess will not join Chevron board - Hess Corporation (HES) announced that the Federal Trade Commission antitrust review of the Chevron-Hess merger has been completed, satisfying one of the closing conditions for the transaction. "We are very pleased that our merger with Chevron has cleared this significant regulatory hurdle. This transaction continues to be an outstanding deal for Hess and Chevron shareholders and will create a premier integrated energy company that is ideally positioned for the energy transition," said CEO John Hess. "To facilitate completion of the merger, Hess and Chevron have agreed that Mr. Hess will not be appointed to the Chevron Board of Directors in order to address a concern raised by the FTC about Mr. Hess' communications with a limited number of OPEC officials. However, Mr. Hess will serve as an advisor and representative for Chevron on government relations and social investments in Guyana as well as on support for the Salk Institute's Harnessing Plants Initiative. The Hess Board of Directors believes that the competitive concern raised by the FTC about Mr. Hess' communications is without merit, and fully supports Mr. Hess in his role as CEO of Hess Corporation. Mr. Hess' public and private communications with OPEC officials were consistent with his communications with U.S. government officials, the International Energy Agency and global business leaders on what will be needed to ensure an affordable and orderly energy transition... Over the past five years, Hess Corporation has had the highest cash flow reinvestment rate of any oil company - majors and independents - and has been the only oil company to reinvest in excess of its cash flow1 in order to grow oil and gas supply... Completion of the merger remains subject to the Merger Agreement's closing conditions, including the satisfactory resolution of ongoing arbitration proceedings regarding preemptive rights in the Stabroek Block joint operating agreement," the company added.

11:05 EDT Chevron confirms Hess merger clears FTC antitrust review - Chevron (CVX) announced the Federal Trade Commission completed antitrust review of the company's merger with Hess Corporation (HES), satisfying a key closing condition for the transaction. "This is an important step toward completing the merger, which will benefit our shareholders, the industry, and the country of Guyana, and add world class assets to our already advantaged portfolio. We look forward to completing the transaction and welcoming Hess into our company," said Chevron Chairman and CEO Mike Wirth. "To facilitate completion of the merger, Hess and Chevron have agreed that Hess CEO John Hess will not be appointed to the Chevron Board of Directors. Instead, Mr. Hess will serve as an advisor to Chevron on government relations and social investments in Guyana as well as on support for the Salk Institute's Harnessing Plants Initiative... Completion of the merger remains subject to other closing conditions, including the satisfactory resolution of ongoing arbitration proceedings regarding preemptive rights in the Stabroek Block joint operating agreement. Chevron remains confident that the arbitration process will affirm the company's position. Hess shareholders approved the merger agreement in May 2024," the company added.

10:58 EDT New Fortress Energy says FLNG asset achieves First Full Cargo, Sail Away - New Fortress Energy provided an update on its initial Fast LNG asset located offshore Altamira, Mexico. NFE's FLNG asset has achieved First Full Cargo & Sail Away, with its first full LNG cargo fully loaded onto the Energos Princess and setting sail for Europe. "This is a significant milestone for our Fast LNG installation. Natural gas and power supply are critical components of a sustainable, affordable, and cleaner energy system and we're excited to be able to provide our own gas supply to the world markets and our customers," said Wes Edens, Chairman and CEO of New Fortress Energy.

10:39 EDT FTC order prohibits Chevron from appointing Hess CEO to board - Tre Federal Trade Commission Chair Lina Khan, joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro Bedoya, said in a statement: "The Organization of the Petroleum Exporting Countries is a cartel that, for decades, has enjoyed outsized control over oil prices in the United States. When OPEC and its allies, collectively known as OPEC+, decide to limit or cut back oil production, American consumers pay more at the pump and American businesses face higher costs...Today's complaint identifies statements by Hess Corporation CEO John Hess that signaled support for efforts by OPEC+ to stabilize production. The proposed order would prohibit Chevron Corporation from appointing Mr. Hess to its Board of Directors. This action builds on the Commission's action in Exxon-Pioneer, which surfaced troubling statements by Pioneer CEO Scott Sheffield that suggested efforts to coordinate with members of OPEC+. Commissioners Ferguson and Holyoak dissent from this matter, as they do not believe that a CEO communicating with a foreign cartel about output should be central to the antitrust analysis here...The Commission's actions in Chevron-Hess and Exxon-Pioneer mark an important step towards ensuring that U.S. oil producers are serving as a competitive check on OPEC+ rather than subordinating their independent decision-making to the goals set by a cartel." Reference Link

10:34 EDT QMMM Holdings Ltd trading halted, volatility trading pause

10:22 EDT New Fortress Energy trading resumes

10:15 EDT New Fortress Energy determines to delay payment of dividend - New Fortress Energy announced that the Company has determined to delay the payment of the company's previously declared 10c per share Class A common stock dividend, with a record date of September 13, 2024, until such time as the Company has reached an agreement with its noteholders to address the Company's near-term maturities and liquidity requirements. The Company expects to reach an agreement with its noteholders in the near future, after which the Company will reevaluate the payment of the Dividend, including with respect to its amount and the timing of any potential payment.

10:06 EDT Fairfax Financial to acquire controlling ownership of Peak Achievement Athletics - Peak Achievement Athletics announced that certain affiliates of Fairfax Financial will acquire all the equity interests in Peak currently owned by Sagard Holdings, giving Fairfax control over Peak and its stable of brands including Bauer Hockey, Cascade Lacrosse and Maverik Lacrosse. In 2017, Fairfax and Sagard purchased Peak, which has a portfolio of leading global brands that includes BAUER, CASCADE and MAVERIK. With its roots starting in Kitchener, Ontario, in 1927, Bauer Hockey is the leading hockey equipment and apparel manufacturer in the world and the No. 1 brand in the game. Cascade Lacrosse and Maverik Lacrosse combine to be the leader in lacrosse head protection and equipment. The transaction is expected to close in the fourth quarter of 2024.

10:01 EDT Amentum falls -7.2% - Amentum is down -7.2%, or -$1.84 to $23.83.

10:00 EDT Jacobs falls -15.7% - Jacobs is down -15.7%, or -$24.41 to $131.12.

10:00 EDT Noah Holdings rises 15.3% - Noah Holdings is up 15.3%, or $1.69 to $12.75.

09:58 EDT Universal Health falls after jury finds Cumberland subsidiary liable - In a regulatory filing earlier, Universal Health Services noted that Cumberland Hospital for Children and Adolescents, or "Cumberland," an indirect subsidiary of the company, is a defendant in multi-plaintiff lawsuits filed in the Circuit Court for Richmond, Virginia, relating to allegations of inappropriate sexual contact during medical examinations by Dr. Daniel Davidow, an independent contractor and the former medical director for Cumberland. "The Company and UHS of Delaware, Inc., our administrative services subsidiary, were also named as co-defendants in the Cumberland Litigation. Plaintiffs have asserted claims of negligence, assault and battery against Dr. Davidow, false imprisonment, violations of the Virginia Consumer Protection Act, and vicarious liability for Dr. Davidow's conduct against Cumberland, the Company, and UHS Delaware. All defendants have denied liability. The claims asserted by three of the plaintiffs in the Cumberland Litigation were consolidated for trial in September of 2024. The Company and UHS Delaware were dismissed from the action during trial. On September 27, 2024, a jury entered a verdict finding Dr. Davidow and Cumberland liable and awarded these three plaintiffs combined compensatory damages of $60 million for all liability theories, an additional combined $180 million in trebled damages for violation of the VCPA, and an additional combined $120 million in punitive damages. Cumberland is evaluating all legal options and intends to challenge this verdict, including the amounts awarded in the verdict, in post-trial proceedings and on appeal. Based upon Virginia law, we expect that the punitive damage amount should be reduced to a combined maximum of $1.05 million as a matter of law. There are approximately 40 additional plaintiffs making similar allegations with claims pending in the Cumberland Litigation. As previously disclosed on Form 8-K on April 1, 2024, and Forms 10-Q for the quarterly periods ended March 31, 2024 and June 30, 2024, the Pavilion Behavioral Health System, an indirect subsidiary of the Company, was a defendant in a lawsuit filed in Champaign County, Illinois, relating to the sexual assault of one minor patient by another minor patient in 2020. The case went to trial in March 2024, and on March 28, 2024, a jury returned a verdict for ordinary negligence and awarded compensatory damages of $60 million and punitive damages of $475 million and a related judgment was entered against the Pavilion. Based on a search of verdicts in comparable cases, the magnitude of this verdict was unexpected and is unprecedented for a single-plaintiff injury case of this type in Champaign County, Illinois. The Pavilion has filed post-trial motions challenging the judgment, which were heard in August 2024, and are awaiting a decision by the court. The Pavilion will pursue an appeal as appropriate depending on the trial court's resolution of post-trial motions. We are uncertain as to the ultimate financial exposure related to the above-mentioned Cumberland and Pavilion matters and we can make no assurances regarding their outcomes, or the amounts of damages that may be held recoverable after post-judgment proceedings and appeals. While Cumberland and Pavilion have professional liability insurance to cover a portion of these amounts, the resolution of these matters may have a material adverse effect on the Company. Without reduction for any potential amounts related to the above-mentioned Cumberland and Pavilion matters, the Company and its subsidiaries have aggregate insurance coverage of approximately $221 million remaining under commercial policies for matters applicable to the 2020 policy year (in excess of the applicable self-insured retention amounts of $10 million per occurrence for professional liability claims and $3 million per occurrence for general liability claims). In the event the resolution of the Cumberland and/or Pavilion matters exhausts all or a significant portion of the remaining commercial insurance coverage available to the Company and its subsidiaries for claims that occurred in 2020 (the applicable year for substantially all of the Cumberland matters, and the Pavilion matter, as discussed above), or it requires the posting of large bonds or other collateral during appeal processes, our future results of operations and capital resources could be materially adversely impacted," the filing stated. In Monday morning trading, shares of Universal Health Services have fallen $12.75, or 5.5%, to $217.17. Reference Link

09:48 EDT Stellantis falls -13.0% - Stellantis is down -13.0%, or -$2.10 to $13.96.

09:48 EDT Jacobs falls -16.0% - Jacobs is down -16.0%, or -$24.89 to $130.64.

09:47 EDT Zeekr rises 15.0% - Zeekr is up 15.0%, or $3.16 to $24.25.

09:45 EDT ACRI Capital Acquisition Corp trading resumes

09:40 EDT ACRI Capital Acquisition Corp trading halted, volatility trading pause

09:35 EDT SLB, ADNOC Drilling, Patterson-UTI to create JV Turnwell Industries - SLB (SLB) announced an agreement to create Turnwell Industries, a joint venture with ADNOC Drilling, SLB and Patterson-UTI (PTEN). The JV will allow the three companies to leverage leading innovations in AI, smart drilling design, completions engineering and production solutions. The JV will focus on the acceleration of UAE's unconventional oil and gas program, with an initial 144 wells scheduled for completion by the end of 2025. SLB will provide integrated drilling, stimulation and completion services, as well as project management, digital capabilities and subsurface support as part of the venture. ADNOC Drilling through its wholly owned subsidiary ADH RSC LTD will hold a 55% majority equity stake, SLB a 30% equity stake and Patterson-UTI the remaining 15% equity stake.

09:33 EDT TPG makes minority investment in Creative Planning, terms not disclosed - Creative Planning announced that TPG has made a substantial minority investment in the Company. TPG is investing in the business through TPG Capital, its U.S. and European private equity platform. Terms of the transaction were not disclosed. TPG Capital joins existing investor General Atlantic, who made a minority investment in 2020, to provide additional resources and expertise to help Creative Planning continue to enhance its service offerings and growth trajectory. Creative Planning President and CEO, Peter Mallouk, will continue to lead the business and maintain a majority stake. Creative Planning is a fast-growing, leading independent wealth management firm that provides comprehensive financial planning-led wealth management solutions, delivering a best-in-class client experience. A trusted partner with a track record of client-led success, Creative Planning and its affiliates currently have more than $375 billion in combined assets under management and advisement across all 50 states and 90 countries.

09:28 EDT Highwoods Properties reports no 'notable' damage from Hurricane Helene - Highwoods Properties reports after having conducted a thorough assessment of its Florida, Georgia, North Carolina and Tennessee properties that its buildings have not sustained any notable damage. Ted Klinck, President and CEO stated, "We are fortunate all members of the Highwoods family are safe. Our team did terrific work preparing for the hurricane and we are thankful to have fared so well. Our thoughts and prayers are with all those who have been hit hard by this storm and need support from our greater community."

09:26 EDT Cytokinetics presents additional data from SEQUOIA-HCM trial - Cytokinetics announced that additional analyses synthesizing data from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, were presented virtually at the Heart Failure Society of America Annual Scientific Meeting by Martin Maron, M.D., Director of the Hypertrophic Cardiomyopathy Center at the Lahey Hospital and Medical Center. The presentation was simultaneously published in the Journal of the American College of Cardiology. In these responder analyses of data from SEQUOIA-HCM, key integrated clinical assessments, commonly relied upon by practicing cardiologists to inform treatment choice and response, were analyzed following 24 weeks of treatment with aficamten or placebo in the study population: complete hemodynamic response, relief of symptoms, enhanced exercise capacity, and cardiac biomarker response. Comparing patients treated with aficamten to placebo, 68% vs 7% demonstrated a complete hemodynamic response, 71% vs 42% experienced relief of limiting symptoms, 46.5% vs 24% showed enhanced exercise capacity and 84% vs 8% demonstrated a substantial response in cardiac biomarkers. Overall, 97% of patients treated with aficamten achieved one or more clinically relevant outcomes, 62% achieved at least three outcomes and 23% achieved all four outcomes. For each of the four outcomes assessed in these analyses, the number needed to treat was fewer than 5 patients. In a responder analysis of functional capacity, 42% of patients on aficamten and 14% of patients on placebo were responders, for a difference vs. placebo of 29% and an NNT of 3. Additionally, among patients treated with aficamten who were eligible for septal reduction therapy at baseline, 88% were no longer eligible at 24 weeks.

09:19 EDT WidePoint awarded federal contract for MobileAnchor Derived Digital Credentials - WidePoint has been awarded a new one-year agreement for MobileAnchor Derived Digital Credentials for a Federal Civilian Agency. WidePoint will provide identity and access management services and support through its recently developed proprietary MobileAnchor Derived Digital Credential.

09:17 EDT BloomZ participates in audio production of 'The Legend of Heroes' - BloomZ participated in the audio production of "The Legend of Heroes: Kai no Kiseki -Farewell, O Zemuria-," a science fantasy role-play videogame. Developed by Nihon Falcom Corporation, The Legend of Heroes: Kai no Kiseki -Farewell, O Zemuria- is a part of a broader series that is now available for online purchase across Asia, The Legend of Heroes franchise. BloomZ was engaged by Nihon Falcom Corporation as the preferred vendor for audio production, given the Company's ability to develop high-quality audio engineering. The Company is expecting significant growth in the global gaming industry and believes such growth will foster the demand for premium graphics and audio production, resulting in greater demand for BloomZ's services.

09:16 EDT Peraso announces purchase order for DUNE Platform from Kenyan WISP - Peraso announced the receipt of a purchase order for its DUNE platform from a wireless Internet service provider in Kenya. This order marks a step forward in the deployment of 60GHz technology in Africa.

09:15 EDT Innovation Beverage Group appoints Genevieve Jodhan as CSO - Innovation Beverage Group announced the appointment of Genevieve Jodhan as Chief Sales Officer. Genevieve joined Angostura Holdings Limited, the brand owner of cocktail bitters brand, Angostura Bitters, in 2007. During her 11+ years at Angostura, she moved through five executive appointments, from Supply Chain Operations to Export Business Development, International Sales, and Marketing and, in 2017, she became the company's first female Chief Executive Officer.

09:13 EDT Jerash Holdings announces results of 2024 Annual Meeting - Jerash Holdings announced the results of its annual meeting of stockholders, conducted on September 27, 2024: All five nominated directors submitted for stockholder approval were re-elected, including: Choi Lin Hung; Wei Yang; Ibrahim H. Saif; Bill Korn; and Mak Chi Yan. The directors will serve a one-year term until the 2025 annual meeting of stockholders. The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers. The Company's stockholders approved, on an advisory basis, one year as the preferred frequency of the stockholders' approval of the compensation of the Company's named executive officers. In light of the voting results, the Company will include a stockholder vote on the compensation of its named executive officers in its proxy materials annually until the next required advisory vote on the frequency of stockholder advisory votes on the compensation of the Company's named executive officers.

09:12 EDT Silynxcom announces $740,000 in orders from Israel Defense Forces - Silynxcom has received additional orders from the Israel Defense Forces in the amount of $740,000, adding to the $815,000 worth of orders secured since the beginning of July 2024. This brings the total accumulated orders from the IDF to approximately $1,550,000 since the beginning of July 2024. This latest order signals Silynxcom's growth in the military tactical communication equipment market.

09:11 EDT LPL Financial appoints Cheri Belski as head, investment management solutions - LPL Financial announced that Cheri Belski has joined the firm as executive vice president and head of investment management solutions. Belski will be responsible for leading key investment efforts, including LPL Research, Investment Products and Advisory Platforms, as well as LPL's Retirement Partners business. Belski brings more than 25 years of experience to LPL, most recently having served as global head of product at T. Rowe Price, where she was responsible for setting the vision for the firm's product development and their strategy in the private markets. At LPL she will be instrumental in driving strategic objectives and empowering the firm's 23,000+ advisors and approximately 1,000 institutions to deliver exceptional advice and run thriving businesses through product differentiation and optionality.

09:09 EDT Ardent Health added to Russell 2000 and 3000 Indexes - Ardent Health has been added as a member of the broad-market Russell 3000 Index and Russell 2000 effective Monday, September 23 as part of the quarterly U.S. Russell Index Initial Public Offering IPO update. "We are pleased to join the Russell 3000 Index and look forward to building awareness around the Ardent growth story while increasing our exposure to new investor audiences," said Ardent President and Chief Executive Officer Marty Bonick. "Ardent Health's inclusion is an important milestone and underscores our strategic focus on delivering sustainable growth and value as we build a consumer-focused ecosystem of care in the communities we serve."

09:08 EDT SS&C completes acquisition of Battea-Class Action Services - SS&C Technologies announced it has completed its acquisition of Battea-Class Action Services, a market-leading provider of securities class action claims and settlement recovery services. The purchase price is approximately $670 million, subject to certain adjustments. "We are pleased to welcome Battea's employees, customers and partners," said Bill Stone, SS&C's Founder and CEO. "We see natural synergies between Battea and SS&C. Battea helps over 900 banks, asset managers, hedge funds and proprietary trading firms receive the maximum distribution of entitled settlements. We look forward to working together to bring these sophisticated new capabilities to clients."

09:07 EDT RTX receives U.S. Navy contract for ESSM Block 2 missiles - Raytheon, an RTX business, has received a $525 million contract from the U.S. Navy to produce ESSM Block 2 missiles and spares for the U.S. and allied nations. ESSM Block 2 is a short to medium-range, ship-launched, dual-mode, guided missile that has increased maneuverability and improved performance over its Block 1 predecessor. "The role of self-ship and local area defense has become increasingly important, and ESSM Block 2 delivers critical capability in this mission," said Barbara Borgonovi, president of Naval Power at Raytheon. "By partnering with the U.S. Navy and allied navies, we're ensuring this versatile system is ready to support our fleets around the world."

09:06 EDT Ramaco Resources appoints Sundaresan as SVP of Technology - Ramaco Resources announced it has hired Dr. Vishnu Sundaresan as senior vice president, SVP, of Technology to help lead the company's expanding rare earth element and carbon products activities. In his role, Dr. Sundaresan will chart Ramaco's technology strategy and oversee the development and implementation of innovative technology solutions to support the company's REE and coal to advanced carbon products growth.

09:04 EDT Castor Maritime acquires Kamsarmax bulk carrier vessel for $29.95M - Castor Maritime has entered, through a separate wholly-owned subsidiary, into an agreement with an unaffiliated third-party to acquire a 2020-built Kamsarmax bulk carrier vessel for a purchase price of $29.95 million. The Company expects to finance the acquisition with cash on hand. The acquisition is expected to be concluded by taking delivery of the vessel during October 2024 and is subject to the satisfaction of certain customary closing conditions.

09:03 EDT MediciNova to support NIH-funded EAP trial to evaluate MN166 in ALS - MediciNova announced that the National Institutes of Health - Neurological Disorders and Stroke has awarded $22 million for an intermediate size Expanded Access Protocol to evaluate the efficacy of MN-166 in Amyotrophic Lateral Sclerosis. In collaboration with an academic group, MediciNova will provide investigational drug MN-166, regulatory support, and safety monitoring support. The NIH grant is supported by the Accelerating Access to Critical Therapies for ALS Act signed into law by President Biden. Expanded Access, also referred to as Compassionate Use, is an FDA-regulated pathway that allows individuals with a serious and life-threatening disease to access an investigational drug that is not yet approved by the FDA. This EAP trial will allow individuals with ALS who are not eligible to participate in the COMBAT-ALS trial to receive treatment with MN-166. The EAP will evaluate neurofilament light, a biomarker for neuron damage, and clinical data in two hundred ALS patients treated with MN-166.

09:00 EDT Twin Vee PowerCats to launch redesign of BayCat boat - Twin Vee PowerCats announced plans to launch a redesigned 22-foot BayCat boat, adding it to the Company's expanding product line. Set to debut in early 2025, Twin Vee's best-selling bay boat is back. The 220 BayCat has been reimagined to provide the best ride in a compact, towable package. Offering the stability and smooth handling that Twin Vees are known for, the 220 BayCat is designed to be ideal for any water adventure.

08:58 EDT XS Financial taken private by Mavik Capital, Axar Capital - XS FINANCIAL announced the closing of its agreement to be taken private by Mavik Capital Management and Axar Capital Management. The Transaction establishes XS as a private company and positions it to expand its platform in the growing equipment financing space. With the deep lending expertise and collective resources of both Mavik and Axar, XS will be able to further scale and diversify its offerings to provide flexible financing solutions that meet the evolving needs of middle-market U.S. businesses across a variety of industries. XS previously announced that it had entered into a definitive agreement to be taken private on June 24, 2024, and the Transaction was approved by XS securityholders at the Company's general and special meeting held on September 9, 2024. Under the terms of the Transaction, Mavik and Axar acquired all of the issued and outstanding subordinate voting shares and proportionate voting shares of XS for a cash purchase price of Cdn$0.05265 per SV Share and Cdn$52.65 per PV Share. All stock options and share purchase warrants outstanding immediately prior to the effective time of the Transaction were automatically cancelled without any payment to the holders. The Transaction was effected by way of a court-approved plan of arrangement under Section 288 of the Business Corporations Act. As a result of the closing of the Transaction, XS's subordinate voting shares will be delisted from the Canadian Securities Exchange and the OTCQB.

08:54 EDT Kartoon Studios provides business update on Mainframe Studios - Kartoon Studios provided a business update for its affiliated animation production arm and largest revenue unit, Mainframe Studios. The Company is reporting that Mainframe Studios is moving toward continued growth amid a strong business rebound following the settlement of the WGA and SAG strikes. The studio has secured series orders for over 145 episodes, strengthening a continuing pipeline through 2025 and 2026. It presently has four series in production with industry giants, including Spin Master, Sony Kids, and Disney. "Over the past year, Mainframe Studios has experienced a significant increase in deal flow, signaling a strong business recovery, following the resolution of the Writers Guild of America and Screen Actors Guild disputes in late Q3 and early Q4 of 2023," said Brian Parisi, CFO of Kartoon Studios. "In the second quarter of 2024, Mainframe Studios' production demand rebounded following the resolution of labor disputes. We have built a highly scalable infrastructure and continue to enhance operational efficiency." Mainframe Studios has four series currently in production for streaming services and leading broadcasters. They include the hit series Unicorn Academy for Spin Master, which premiered on Netflix, and the hit series SuperKitties for Sony Kids and Disney+. Mainframe Studios is also producing an unannounced 80 x 11-minute episodes of a 2D animated series. In addition, Mainframe Studios recently announced that it is co-producing the animated kids series Andrew the Big BIG Unicorn with Pirate Size Productions and Infinite Studios. The ABC, CBC, and SRC are the commissioning broadcasters, and Kartoon Studios will retain international distribution, licensing, and merchandising.

08:49 EDT Foremost Lithium announces data for Annual General, Special Meeting - Foremost Clean Energy announced that, further to its announcement of July 30, 2024 with respect to the proposed spin-out of the Winston Group of Gold and Silver Properties pursuant to a statutory plan of arrangement under the Business Corporations Act, it has scheduled its Annual General and Special Meeting of shareholders for December 09, 2024 at 11:00 a.m. Foremost shareholders will vote on the Arrangement, among other things, at the Meeting. Full details are provided below under "Further Details of AGSM". Pursuant to the Arrangement, the Properties will be transferred to a newly incorporated company, named Rio Grande Resources and Foremost Shareholders will exchange each outstanding common share of Foremost for one new Foremost common share and two common shares of Rio Grande. The Arrangement, if completed, will result in Foremost retaining an approximate 19.95% interest in Rio Grande. In connection with the Arrangement, the Company has filed an updated independent technical report for the Properties prepared in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects titled "Technical Report for the Winston Gold-Silver Project: Sierra County, New Mexico, USA". The Properties consist of one-hundred-forty-seven unpatented lode mining claims and two patented mining claims in Sierra County and Catron County, New Mexico. The Properties cover 1,229 hectares in the Black Range/Chloride Mining District of central New Mexico and are comprised of three historic past producing gold and silver mines: Ivanhoe, Emporia and Little Granite. Exceptional results from property-wide confirmatory sampling completed in 2021 included many high-grade samples including 41.5 g/t Gold and 4,610 g/t Silver on newly staked claims. Additional samples from these three mines returned peak values of 66.5 g/t gold and 2,940 g/t silver from Little Granite, 26.8 g/t gold and 1,670 g/t silver from Ivanhoe, and 46.1 g/t gold and 517 g/t silver from Emporia. An application has been submitted to the CSE to list Rio Grande Shares upon completion of the Arrangement. It is a condition of the completion of the Arrangement that the CSE, and if required, the NASDAQ, will have conditionally approved the Arrangement, including the listing of the new Foremost common shares and the Rio Grande Shares. In connection with the Arrangement, Rio Grande is expected to complete a private placement of subscription receipts for approximate aggregate gross proceeds of $1,750,000, with each subscription receipt automatically converting upon the satisfaction or waiver of conditions precedent to the Arrangement and the listing of the Rio Grande Shares on the CSE into Rio Grande Shares. The gross proceeds of the Private Placement will be held in escrow pending the satisfaction of the release conditions.

08:46 EDT Ascendis Pharma submits sBLA to FDA for TransCon hGH - Ascendis Pharma has submitted a supplemental Biologics License Application to the U.S. Food & Drug Administration for TransCon hGH in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency. The submission is based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled and active-controlled trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily hGH in adults with GHD. The trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake with approximately equivalent hGH mg/week for TransCon hGH and daily hGH. TransCon hGH demonstrated superiority on its primary efficacy and key secondary efficacy endpoints at Week 38, with TransCon hGH-treated patients showing a statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo. TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily hGH.

08:43 EDT Safety Shot to be available at 7-Eleven stores in Chicago - Safety Shot announced that 4 oz. bottles of Safety Shot will soon be sold at 7-Eleven convenience stores in the Chicago area. Working in a partnership with the President and board members of the Francise Owners Association Chicago, Safety Shot will launch its convenient on-the-go 4 oz. bottles at 315 7-Eleven stores in the Chicago area. The product will have a counter-top placement and will be priced at $5.99 each and $10 for two.

08:41 EDT ACM Research's operating subsidiary provides backlog data - As of September 30, 2024 and September 27, 2023, ACM Shanghai's total backlog amounted to RMB 6,764.6 million, and RMB 6,795.8 million respectively. The total backlog figures include a mix of orders for tools that have been shipped but not yet recognized as revenue under Chinese generally accepted accounting principles, and orders for tools expected to be shipped at a future date.

08:39 EDT Strong Global Entertainment, Fundamental Global complete combination - Fundamental Global has completed its combination with Strong Global Entertainment pursuant to a previously announced arrangement agreement. The combination received overwhelming support, with more than 99% of the shares cast at the Strong Global shareholders meeting on September 17, 2024 voting to approve the transaction. Shareholders of Strong Global Entertainment will receive 1.5 common shares of Fundamental Global for each common share they hold.

08:37 EDT Kezar Life Sciences suspends enrollment of PALIZADE trial - Kezar Life Sciences announced the voluntary cessation in enrollment of new patients and dosing of ongoing patients in the Phase 2b PALIZADE clinical trial, pending further evaluation. PALIZADE is a global, placebo-controlled, randomized, double-blind Phase 2b clinical trial evaluating the efficacy and safety of two dose levels of zetomipzomib in patients with active lupus nephritis, or LN. Patients in the trial are randomly assigned to receive 30 mg of zetomipzomib, 60 mg of zetomipzomib or placebo subcutaneously once weekly for 52 weeks, in addition to standard background therapy. To date, 84 patients have been enrolled in the PALIZADE trial, and patient safety data are reviewed by an Independent Data Monitoring Committee, or IDMC. Kezar has suspended enrollment and dosing in PALIZADE at the recommendation of the IDMC after their recent review of emerging safety data, including an assessment of four Grade 5 serious adverse events that have occurred during the course of the trial in patients enrolled in the Philippines and Argentina. Review of the data by the IDMC revealed that three of the fatalities showed a common pattern of symptoms and proximity to dosing, and additional non-fatal SAEs showed a similar proximity to dosing. Kezar remains blinded as to which patients were on the zetomipzomib or placebo treatment arms. Kezar has not observed any instances of death or serious opportunistic infections in prior clinical studies of zetomipzomib. Kezar's ongoing Phase 2a PORTOLA clinical trial of zetomipzomib in patients with autoimmune hepatitis has completed enrollment and remains active at this time. To date, no Grade 4 or 5 SAEs have been observed in the PORTOLA clinical trial. Kezar's decision to pause enrollment and dosing on PALIZADE enables time to evaluate the totality of data regarding the SAEs and determine next steps and potential risk mitigation strategies. The company has notified all study investigators and is notifying regulatory authorities, including the FDA and the European Medicines Agency, of its decision. At this time, a formal Investigational New Drug clinical hold has not been issued. If Kezar receives a clinical hold letter from the FDA, it will review the content and determine next steps.

08:36 EDT Windtree Therapeutics announces Phase 2b topline results of istaroxime - Windtree Therapeutics announced topline clinical results for its Phase 2b SEISMiC Extension Study of istaroxime in heart failure patients in early cardiogenic shock. Early cardiogenic shock is caused by a failing heart and is characterized by low blood pressure, leaving the patient at risk of developing inadequate blood flow to vital organs leading to high morbidity and mortality. Istaroxime is a novel first-in-class investigational therapy that is intended to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining renal function with a generally favorable safety profile. Istaroxime has been studied in four positive Phase 2 trials enrolling patients with acute heart failure and early cardiogenic shock due to heart failure. The Phase 2b SEISMiC Part B Extension Study in early cardiogenic shock randomized 30 subjects and was conducted in the United States, Europe and Latin America. The study is focused on istaroxime's observed ability to correct low blood pressure and to improve cardiac function and other parameters over 96 hours of close monitoring with the final visit at 30 days. The results build upon the positive results reported previously in the Phase 2b SEISMiC Part A study. The Part B study included hospitalized patients with SCAI Stage B cardiogenic shock with persistent hypotension due to acute heart failure and evaluated two different dose regimens of istaroxime compared to placebo. Patients in the active treatment groups received infusions of istaroxime for up to 60 hours, with one group receiving a decreasing istaroxime dose over time and the second group receiving a constant istaroxime dose. The study tested an extended dosing duration of istaroxime compared to previous studies, where treatment was limited to 24 hours, to determine the potential for additional benefit and, along with dose titration, to determine the optimal dosing regimen for an anticipated late-stage Phase 3 clinical trial. For the primary endpoint evaluating blood pressure, subjects from Part A and Part B of SEISMiC were prospectively combined for analysis. In the analysis of Part B, all istaroxime-treated patients were compared to the placebo group. For certain endpoints in Part B, the dose-response between the two different istaroxime dose regimens was compared. The study met its primary endpoint in significantly improving systolic blood pressure over six hours, with the combined Part A and Part B SEISMiC istaroxime group performing significantly better compared to the placebo group. Despite the smaller number of patients in SEISMiC Part B, the SBP AUC was also significantly improved by istaroxime compared to placebo. The improvements in SBP AUC at 24 hours in the combined Part A and Part B analysis were also significantly increased by istaroxime. In Part B alone, the istaroxime group was significantly better compared to the placebo group. With the longer istaroxime dosing in Part B, the SBP AUC was significantly improved at 48 hours and 60 hours as well. SEISMiC Part B results: Cardiac output was improved during the infusion by approximately 15% in the istaroxime group over the course of treatment. Heart rate tended to decrease and there was no statistically significant increase in heart rate versus placebo in the istaroxime group. At 12 and 24 hours, patients in the istaroxime group experienced statistically significant reductions in heart rate. Increasing heart rate contributes to greater cardiac oxygen demand and workload, and therefore can lead to deleterious effects in heart failure patients. Pulmonary capillary wedge pressure is elevated in this patient population and also was elevated in our study subjects at baseline. Istaroxime treatment reduced PCWP significantly more than placebo within six hours and the effect persisted through 60 hours. PCWP is a measure of cardiac filling pressure and when high contributes to worsening heart failure and pulmonary edema. Mixed venous oxygen saturation, an assessment of organ perfusion, was significantly improved by 12 hours, and remained significant through 48 hours. The improvement versus placebo generally persisted through a 60-hour assessment. A low SVO2 can indicate that cardiac output is not high enough to meet the tissue oxygen needs. Renal function measured by estimated glomerular filtration rate was improved in this study in the istaroxime group compared to placebo at all time points reaching statistical significance at 48 hours. Clinical signs and symptoms of congestion and heart failure improved in both groups. The New York Heart Association classification of heart failure severity significantly decreased in the istaroxime group at 24 hours, 48 hours, and 72 hours and was similar to placebo at 96 hours. Worsening heart failure reported as a serious adverse event occurred less frequently in the istaroxime group compared to placebo 5.3% versus 18.2%, respectively. The istaroxime safety profile in Part B was favorable and generally consistent with what has been previously reported in other istaroxime clinical trials. Treatment-emergent adverse events were reported more frequently in the istaroxime group at 78.9% compared to 45.5% in the placebo group, predominantly due to nausea, vomiting, infusion site discomfort and headache that have been observed previously with istaroxime. Serious adverse events were infrequent and occurred at a similar frequency in both the istaroxime and placebo groups. Importantly, consistent with previous findings, istaroxime did not increase clinically significant arrythmias compared to the placebo group.

08:34 EDT Anixa Biosciences announces submission of protocol amendment for CAR-T trial - Anixa Biosciences announced that it and partner Moffitt Cancer Center have submitted an amendment to the current protocol that governs its ongoing clinical trial utilizing a CAR-T therapy to treat ovarian cancer. A key change in the protocol provides a second dose of the therapy to patients who might benefit from an additional dose. Previously, Anixa and Moffitt sought and received approval of a single patient IND application to enable a second dose for a single patient who, upon examination of tumor obtained from a biopsy, exhibited cellular infiltration and necrosis, indicating biologic activity of the CAR-T. This amendment will permit all potential patients to receive another leukapheresis and a second dose of CAR-T, without submitting individual INDs for each patient.

08:33 EDT Worksport provides progress update on ISO 9000 certification - Worksport is progressing towards achievement of ISO 9000 certification at its state-of-the-art West Seneca, NY factory anticipated by early-mid 2025. This certification reflects Worksport's commitment to quality manufacturing and is expected to support potential growth in key future markets including government contracts, Original Equipment Manufacturers relationships and larger distribution networks. OEM relationships may lead to future direct and indirect sales opportunities to domestic car brands.

08:32 EDT Quantum Computing extends collaborative agreement with LANL - Quantum Computing announced the extension of its Cooperative Research and Development Agreement, CRADA, with the Los Alamos National Laboratory, LANL. This strategic collaborative agreement focuses on QCi's new entropy quantum optimization machine, Dirac-3, and its capabilities to quickly and efficiently solve highly complex problems associated with quantum simulations, social networks, protein structure prediction, and telecommunications.

08:29 EDT Ocuphire Pharma announces publication of Phase 3 results of RYZUMVI - Ocuphire Pharma announced the publication of full results from two pivotal Phase 3 clinical trials that evaluated the safety and efficacy of RYZUMVI for the treatment of pharmacologically-induced mydriasis in the peer-reviewed journal Ophthalmology. The results demonstrated that Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, rapidly and effectively reversed pharmacologically-induced pupil dilation with a favorable safety profile. As previously reported by Ocuphire, in both trials a statistically significant greater percentage of subjects treated with Phentolamine Ophthalmic Solution 0.75% achieved reversal of pharmacologically-induced mydriasis at 90 minutes compared to those receiving placebo, which was the primary endpoint. In the MIRA-2 trial, 48.9% of subjects treated with Phentolamine Ophthalmic Solution 0.75% achieved reversal versus 6.6% in the placebo group. In the MIRA-3 trial, 58% of subjects treated with Phentolamine Ophthalmic Solution 0.75% achieved the primary endpoint versus 6% in the placebo group. Effects were observed as early as 60 minutes following administration, with significant improvements in pupil diameter at that timepoint and at every timepoint measured up to 24 hours following administration in both trials. More subjects receiving Phentolamine Ophthalmic Solution 0.75% reported a perceived benefit in the resolution of visual symptoms caused by pharmacologically-induced mydriasis compared to placebo, with statistically significant differences noted as early as one hour following administration. Fewer subjects treated with Phentolamine Ophthalmic Solution 0.75% had residual dilation at 24 hours post-dilation, compared to placebo-treated subjects. Phentolamine Ophthalmic Solution 0.75% exhibited a favorable safety profile, with the most common treatment-emergent adverse events being mild and transient, including conjunctival hyperemia, instillation site discomfort and dysgeusia. Phentolamine Ophthalmic Solution 0.75% is approved and marketed as RYZUMVI for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents by Ocuphire's commercial partner. Phentolamine Ophthalmic Solution 0.75% is currently being evaluated in presbyopia and dim light vision disturbances after keratorefractive surgery. The VEGA-3 Phase 3 clinical trial for presbyopia is actively enrolling, and top-line data are expected in the first half of 2025. The LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery is also actively enrolling, and top-line data are expected in the first quarter of 2025.

08:26 EDT Seanergy Marine urges shareholders to vote for Seanergy director nominees - Seanergy Maritime Holdings has commenced mailing of proxy materials to its shareholders in connection with the Company's 2024 Annual Meeting of Shareholders, scheduled to be held on November 4, 2024. Shareholders of record as of the close of business on September 19, 2024, will be entitled to vote at the meeting. The company said, "The Company also mailed a letter to Seanergy shareholders highlighting the commitment of the Board of Directors and management team to delivering value for all Seanergy shareholders and how the Company's continued execution of its strategic plan has it positioned to continue delivering leading and sustainable shareholder returns through the cycle. George Economou - a shipowner and a competitor of Seanergy - has acquired a stake in Seanergy. He has brought litigation and launched a proxy fight against Seanergy seeking to gain effective control over the Company's Board and its corporate strategy by replacing two of the Company's directors with his own closely-associated nominees and calling for the resignations of the rest of Seanergy's Board members. In turn, this would allow Economou's nominees to fill those vacancies, such that the entire Board would be constituted with the nominees of a single shareholder. Based on his extensive track record of destroying shareholder value across multiple publicly listed companies, Economou's blatant attempt to seize effective control over the Company by replacing the entire Board with his own nominees and their appointees would be detrimental to Seanergy's ability to continue to deliver outperformance and would negatively impact shareholder value. The Board of Directors unanimously recommends that shareholders vote on the WHITE proxy card "FOR" Seanergy's nominees and "AGAINST" the Economou proposals."

08:23 EDT Ultralife to acquire Electrochem from Integer for $50M - Ultralife Corporation (ULBI) has signed a stock purchase agreement to acquire all outstanding shares of Electrochem Solutions, to include its state-of-the-art ISO certified technology and manufacturing facility for $50.0 million in cash from Integer Holdings Corporation (ITGR), subject to customary working capital adjustments. The transaction is expected to close by the end of October. Ultralife expects to finance the transaction through its primary lender. Based in Raynham, MA and with over forty years of battery technology experience in critical applications, Electrochem designs and manufactures primary lithium metal and ultracapacitor cells and battery packs serving energy, military and various environmental, industrial and utility end markets on a global basis. For the trailing twelve-month period ended June 30, 2024, Electrochem recorded revenue of $34 million. The transaction is expected to be accretive on an EPS basis for 2025.

08:22 EDT LOBO EV remains 'optimistic about continued momentum' in 2H24 - The company said, "With the successful execution of its growth strategy, including international expansion and product innovation, LOBO remains optimistic about continued momentum in the second half of 2024. The Company plans to launch several new vehicle models and further strengthen its presence in international markets, driving both unit sales and revenue growth."

08:21 EDT LOBO EV anticipates margin improvements in 2H24 - In H1 2024, LOBO increased its research and development spending by 86%, focusing on enhancing product features and developing advanced software solutions to meet customer needs in newly entered markets. The Company also expanded its inventory by 55% to support growing demand and facilitate the roll-out of new vehicle models in the second half of the year. LOBO anticipates margin improvements in H2 2024 as the Company continues to scale operations and optimize its supply chain. The introduction of new vehicle models and increased sales in higher-margin international markets are expected to contribute to improved profitability. LOBO's management remains focused on cost control measures and operational efficiencies to drive sustainable margin expansion in the second half of the year.

08:17 EDT Matthews completes senior notes offering - Matthews International closed on September 27, 2024 on its previously announced private offering of $300 million aggregate principal amount of its 8.625% senior secured second lien notes due 2027. The Notes will pay interest semi-annually in arrears, on April 1 and October 1 of each year, beginning on April 1, 2025. The Notes will mature on October 1, 2027, unless earlier redeemed or repurchased, and are callable in one year. The Company intends to use the net proceeds of the offering, together with borrowings under the senior credit facility under the Credit Agreement, to redeem all of its outstanding senior notes due December 1, 2025 on or about October 24, 2024, and to pay accrued and unpaid interest on the Existing 2025 Notes to, but not including, the date of redemption, and to satisfy and discharge the indenture governing the Existing 2025 Notes.

08:16 EDT Merus announces first patient dosed in LiGeR-HN1 Phase 3 trial - Merus announced that the first patient has been dosed in the Company's phase 3 trial evaluating the efficacy and safety of petosemtamab, a Biclonics targeting EGFR and LGR5, in combination with pembrolizumab, compared to pembrolizumab as first line therapy for patients with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma, referred to as the LiGeR-HN1 trial. Merus has confirmed through feedback with the U.S. Food and Drug Administration that petosemtamab 1500 mg every two weeks is appropriate for further development in HNSCC as monotherapy, and in combination with pembrolizumab.

08:15 EDT Kezar Life Sciences trading halted, news pending

08:13 EDT Casella Waste closes $1.5B amended, restated credit facility - Casella Waste Systems has entered into a $1.5 billion amended and restated credit agreement with Bank of America, N.A. as administrative agent and lender and a syndicate of other lenders. The Credit Facility matures on September 27, 2029 and replaces the Company's prior $1.08 billion credit facility. The Credit Facility provides for an $800 million term loan A facility and a $700 million revolving credit facility, with a $155 million sublimit for letters of credit. The revolving credit facility was undrawn at closing and provides increased liquidity for general corporate purposes, including the execution of the Company's acquisition strategy. The interest rate margin applicable to SOFR based borrowings, including revolving loans, ranges from 1.300% to 2.175% based on consolidated net leverage ratio. The joint lead arrangers of the Credit Facility are BofA Securities, Inc., JPMorgan Chase Bank, N.A., Citizens Bank, N.A., TD Bank, N.A., Wells Fargo Securities, LLC, and Comerica Bank.

08:13 EDT Integer to divest non-medical business for $50M - Integer Holdings Corporation (ITGR) has entered into an agreement to divest its Electrochem business, which focuses on non-medical applications for the energy, military and environmental sectors, to Ultralife Corporation (ULBI). Ultralife is acquiring Electrochem for $50M in cash, subject to customary working capital adjustments, and the transaction is expected to close by the end of October. Going forward, Integer will report the results of its Electrochem business, currently included in its "Non-Medical" segment, as part of discontinued operations. This will include any gain or loss recognized on the sale of the business. The Company intends to use the proceeds from the sale to pay down outstanding debt and for general corporate purposes. In the 2024 full year guidance provided as part of our second quarter 2024 earnings release, we assumed the following in relation to our non-medical segment, adjusted to include $3 million of allocated interest expense as part of discontinued operations: Sales of $36 million. GAAP operating income of $3 million. Non-GAAP adjusted operating income of $4 million. Adjusted EBITDA of $5 million. GAAP net income of $0 million. Non-GAAP adjusted net income of $1 million. GAAP diluted EPS of $0.00. Non-GAAP adjusted EPS of $0.02. The company expects this transaction to be neutral to EPS.

08:11 EDT CareCloud, ChartSwap partner to launch 'CareCloud Powered by ChartSwap' - CareCloud announced a strategic partnership with ChartSwap to launch "CareCloud Powered by ChartSwap." This new collaboration will significantly enhance the way medical records are handled and accessed, enabling CareCloud's providers to focus more on delivering high-quality patient care. Through this partnership, ChartSwap will serve as the dedicated portal for handling Release of Information requests for medical information at CareCloud provider locations. Requestors, including law firms and insurance companies, will now be able to obtain medical records through ChartSwap's secure and user-friendly platform. By eliminating the manual burden associated with processing records requests, the new partnership empowers CareCloud providers to streamline administrative tasks and focus on patient care.

08:10 EDT TAFE issues letter to AGCO shareholders outlining governance opportunities - TAFE issued the following open letter to its fellow shareholders..."Tractors and Farm Equipment is the largest shareholder of AGCO Corporation with ownership of approximately 16.3% of the Company's outstanding shares. We are also a long-term shareholder who has spent more than a decade trying to enable the Company to grow and create enhanced value for all stakeholders. We believe our significant shareholdings and track record of constructive engagement demonstrate that our interests are squarely aligned with your interests. Given our experience allocating capital and operating businesses within the agricultural machinery sector, we have firm conviction in AGCO's future growth potential. As the Company has struggled in recent years to integrate acquisitions and expand into new markets, we have drawn on our experience to provide leadership with pragmatic suggestions. Unfortunately, AGCO has responded by ignoring these ideas, taking measures to disenfranchise TAFE, and isolating our representative on the Board of Directors. This seemingly unjustifiable intransigence has resulted in the deterioration of the Company's competitive position and financial performance versus peers and is now forcing us to deviate from our preferred method of private engagement."

08:09 EDT Blockchain Coinvestors terminates business combo agreement with Linqto - Blockchain Coinvestors Acquisition Corp. I announced that its business combination agreement with Linqto has been terminated. As previously announced, on April 9, 2024, Blockchain Coinvestors Acquisition Corp. I, a Cayman Islands exempted company, entered into a Business Combination Agreement, by and among BCSA, Linqto and BCSA Merger Sub I, Inc.

08:08 EDT Blue Owl Capital completes acquisition of Atalaya Capital's business - Blue Owl Capital announced the completion of its acquisition of the business of alternative credit manager, Atalaya Capital Management. The acquisition was previously announced in July of 2024. Atalaya focuses primarily on asset-based credit investments across consumer and commercial finance, corporate and real estate assets. As of June 30, 2024, Atalaya managed over $10 billion of assets under management. Atalaya's Founding Partner and Chief Investment Officer, Ivan Zinn, has been appointed Blue Owl's Head of Alternative Credit, reporting to Craig Packer, Head of Credit and Co-President of Blue Owl. The completion of the acquisition of Atalaya's business represents a significant expansion of Blue Owl's alternative credit presence and supplements the firm's market leading position in direct lending.

08:06 EDT Air Products completes $1.81B sale of LNG process tech to Honeywell - Air Products announced it has completed the sale of its liquefied natural gas, LNG, process technology and equipment business to Honeywell for $1.81 billion in cash. First announced in July 2024, closing conditions for the transaction have been fully met and regulatory approvals received. The divestiture of the LNG process technology and equipment business is strategic, reflecting Air Products' firm focus on its two-pillar growth strategy to profitably grow its core industrial gases and related equipment businesses, and to deliver clean hydrogen at scale.

08:05 EDT Astria Therapeutics gets ODD from FDA for navenibar to treat HAE - Astria Therapeutics announced that navenibart or STAR-0215, has been granted Orphan Drug Designation for the treatment of hereditary angioedema HAE by the U.S. Food and Drug Administration FDA. Navenibart is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting attack prevention for HAE. Initial results from the Phase 1b/2 ALPHA-STAR clinical trial of navenibart have demonstrated a favorable safety and tolerability profile and a reduction of monthly attack rates by 90-96% when dosed once or twice over six months. "Receiving orphan drug designation for navenibart is an important affirmation of our belief that there is a significant unmet need for people living with HAE," said Jill C. Milne, Ph.D., Chief Executive Officer. "We believe navenibart has the potential to be the market-leading HAE treatment because of its trusted mechanism and modality, efficacy observed to date, and low treatment burden with infrequent dosing, and think that navenibart could change the way that people live with their HAE. We expect to share additional results from the ALPHA-STAR trial in Q4 and to progress navenibart into a Phase 3 trial initiating in the first quarter of 2025." The FDA's Orphan Drug Designation program grants orphan status to medicines intended for the safe and effective prevention, diagnosis, or treatment of rare diseases or disorders that affect fewer than 200,000 people in the United States.

08:05 EDT Mobix Lab submits proposal to acquire Emcore for $3.80 per share in cash - Mobix Labs (MOBX) announced it has submitted a non-binding proposal to the board of directors of Emcore (EMKR) to acquire all of Emcore's outstanding shares for $3.80 per share in cash. Mobix Labs' all cash proposed offer to the Emcore board represents a more than 200% premium over Emcore's current stock price as of September 27. Based upon its 2022 and 2023 10-K filings, Emcore's revenue in its fiscal year ending 9/30/23 grew 115% to $97M from the prior year. Mobix Labs' proposal has the support of its board of directors. Mobix Labs' all cash offer is subject to the approval of the Emcore board of directors, the execution of a definitive agreement between Mobix Labs and Emcore, and any shareholder approval that may be required by law.

08:04 EDT The Oncology Institute announces expansion into Oregon - The Oncology Institute announced its expansion into Oregon with the opening of two new specialty cancer clinics. The clinic locations in Portland and Salem will mark TOI's first capitated partnership in the market, with plans to expand to other markets in the state as additional partnerships develop. Both initial Oregon clinic locations will offer cutting edge cancer care services, offering a vital new option for patients in the Pacific Northwest.

08:01 EDT Infinera says GHG emission reduction targets validated by SBTi - Infinera announced that its greenhouse gas emission reduction targets have been validated by the Science Based Targets initiative. This third-party validation reinforces Infinera's commitment to promoting sustainability in the telecommunications industry through energy-efficient optical networking solution design and environmental, social, and governance initiatives. SBTi is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. SBTi's Target Validation Team has classified Infinera's Scope 1 and Scope 2 target ambitions as in line with keeping global warming to 1.5 degrees C in accordance with the Paris Agreement. SBTi validates that Infinera's 1.5 degrees C-aligned target is currently the most ambitious designation available through SBTi's evaluation process. Infinera's targets as verified by SBTi include: A commitment to reduce absolute Scope 1 and Scope 2 GHG emissions by 85 percent by 2030 from a 2020 base year. A commitment to reduce absolute Scope 3 GHG emissions by 25 percent within the same timeframe. Infinera is making significant progress in minimizing its carbon footprint, having reduced Scope 1 and 2 GHG emissions by 75 percent since 2020. The company also confirmed it is using renewable energy in over 80 percent of its Tier 1 and Tier 2 sites.

07:50 EDT Tharimmune signs nonbinding LOI to merge with Intract Pharma - Tharimmune and Intract Pharma have entered into a nonbinding, exclusive letter of intent pursuant to which Tharimmune will acquire all outstanding shares of privately-held Intract in exchange for newly issued restricted common stock. Under the terms of the LOI, following the execution of a definitive agreement and the closing of the merger, Intract shareholders will own 49% of the total equity in the combined entity, which will be named Tharimmune, Inc., with Intract becoming a wholly owned subsidiary. The company will continue to trade on the Nasdaq Capital Market under the ticker symbol "THAR". Tharimmune believes the merger will position the combined company to reach multiple milestones with significant value-creation potential over the next 24 months, driven by a strong clinical pipeline, a seasoned Board of Directors, a unified management team and the support of current healthcare-focused investors. Furthermore, this transaction aims to expand Tharimmune's product pipeline and reinforce its commitment to pioneering novel treatments, thereby enhancing its competitive position in the high-value, multibillion-dollar biologics market. Beyond expanding Tharimmune's therapeutic pipeline, the proposed transaction, which is expected to close in the first quarter of 2025, is expected to create significant shareholder value by strengthening the company's competitive position in the high-value, multibillion-dollar biologics market. The transaction represents a strategic opportunity for the combined company to strengthen its position in the biotechnology industry, expand its therapeutic pipeline and create long-term value for shareholders. The development of oral biologics holds immense potential to improve patient compliance and overall quality of life. By offering a more convenient and less invasive method of delivery, patients are more likely to adhere to their treatment regimens. This may, in turn, lead to better health outcomes and a higher quality of life for those who require long-term therapy with biologics. Intract's oral biologics delivery platform is designed to protect the molecules as they pass through the harsh environment of the gastrointestinal tract, ensuring they reach their target sites in the diseased tissue or in systemic circulation. This innovative approach holds potential to revolutionize the way biologics are administered, making treatments more accessible and less burdensome for patients. On September 16, 2024, Tharimmune announced it entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor alpha monoclonal antibody, infliximab. Under the terms of the agreement, Tharimmune licensed global development and commercialization rights to Intract Pharma's Soteria and Phloral delivery platform along with an existing supply agreement for infliximab to be used in the oral product development program. That agreement is not impacted by the acquisition letter of intent.

07:45 EDT Brainsway announces $20M private placement with Valor Equity Partners - BrainsWay has entered into a securities purchase agreement with an affiliate of Valor Equity Partners for a private investment financing expected to result in gross proceeds of approximately $20M. In the PIPE, BrainsWay has agreed to issue to Valor an aggregate of 2,103,745 American Depositary Shares, at a purchase price of $9.51 per ADS, a 20% premium above the 30-day volume-weighted average price of the ADSs, and warrants to purchase up to an additional 1,500,000 ADSs at the same price, which may further increase the proceeds from the PIPE up to a total of approximately $34.3M if the Warrants are fully exercised in cash. The Warrants will become exercisable upon issuance thereof at the closing of the PIPE and will remain exercisable for 18 months following their initial issuance date, provided, however, that during such 18-month period, if the Company's ADS closing price for any thirty consecutive trading days exceeds the Exercise Price by 40% or more, the holder of the Warrants shall be required to fully exercise the Warrants in accordance with the terms therein within five trading days. In connection with the PIPE, the Company is granting Valor the right to nominate at least one member to its board of directors so long as Valor holds, directly or indirectly, at least 10% of the outstanding voting rights of the Company and two members to its board of directors so long as Valor holds, directly or indirectly, at least 20% of the issued and outstanding share capital of the Company. Valor has notified the Company that the initial director it designates for nomination as a member to the board of directors will be Mr. Shulkin. The closing of the PIPE and the issuance of the ADSs and Warrants to Valor is subject to customary closing conditions as well as the Company obtaining shareholder approval of the transaction. The Company agreed to file a notice and proxy statement for its extraordinary general meeting of its shareholders for the purpose of obtaining such shareholder approval by no later than ten days following the signing of the securities purchase agreement and hold such meeting within thirty-five days following such filing. The Company intends to use the proceeds from the PIPE for strategic initiatives including to expand market awareness, enhance data analysis capabilities, develop its R&D roadmap, evaluate other potential opportunities in the TMS industry and expand access to Deep TMS.

07:42 EDT DeFi subsidiary launches asset-backed ethereum physical stacking ETP - DeFi Technologies announces the introduction by its subsidiary, Valour Inc., and Valour Digital Securities Limited of its asset-backed Ethereum exchange traded products also known as exchange traded notes on the London Stock Exchange.

07:40 EDT Alterity Therapeutics appoints Abby Macnish Niven as CFO - Alterity announced the appointment of Abby Macnish Niven as the Company's CFO. Macnish Niven has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minett. Ms Macnish Niven consults to a range of listed and unlisted companies in governance, finance and corporate structure. Macnish Niven will replace Mr Phillip Hains, who supported Alterity as CFO from December 2023. Mr Hains continues as Company Secretary.

07:39 EDT Volcon CEO John Kim releases video update on company developments - Volcon ePowersports announced that CEO John Kim has released a video update addressing some developments within the company.

07:38 EDT Gaming and Leisure Properties appoints Brandon Moore as president - Gaming and Leisure Properties announced the promotion of COO, Brandon Moore, to the additional role of President, effective immediately. Mr. Moore will continue to report to the Company's Chairman and CEO, Peter Carlino.

07:37 EDT DocGo appoints Stephen Klasko as chair - DocGo announced the appointment of Stephen Klasko as the new independent, non-executive chair of its board of directors, effective October 1. Klasko will fill the board vacancy created by the resignation of DocGo's outgoing chair of the board, Steven Katz. Klasko currently serves as a special advisor at leading venture capital firm General Catalyst, and as chief medical officer of Abundant Venture Partners.

07:35 EDT Traws Pharma announces topline Phase 1 results for ratutrelvir - Traws Pharma announced topline Phase 1 results for its potential best-in-class COVID candidate, ratutrelvir, an oral inhibitor of the Main protease. "Topline data indicate that administration of ratutrelvir, our product candidate for COVID, as monotherapy, for 10 days to healthy volunteers, showed no treatment related adverse events and demonstrated consistent plasma drug levels in the predicted therapeutic window. We are especially pleased by ratutrelvir's ability to achieve plasma concentrations that are considerably above the EC90 against a comprehensive panel of SARS-CoV-2 viruses, without the need for ritonavir co-administration that can be a source of drug-drug interactions and potential severe side effects," said Werner Cautreels, CEO. "These data provide us with further indication that ratutrelvir has the potential to be a potent, best-in-class, once-a-day, single-dose, 10-day antiviral therapy for COVID. This profile contrasts with Paxlovid, an approved Mpro inhibitor, which requires co-administration of ritonavir, a metabolic inhibitor. We believe that ratutrelvir's ritonavir-free regimen has the potential to reduce the burden of treatment, especially for patients with underlying medical conditions. Based on the Phase 1 data, we have selected the dose for our Phase 2a study, expected to begin in H1 2025." The Phase 1 trial was designed as a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple ascending doses of ratutrelvir, administered as a capsule formulation in 56 healthy, COVID-negative, adult volunteers, randomized three-to-one. The SAD portion of the study evaluated five ratutrelvir dose levels; the MAD segment evaluated two ratutrelvir dose levels, administered once daily for 10 days. This first-in-human study showed no treatment related adverse events reported up to the highest dose. Topline data also showed that once-daily administration of ratutrelvir maintained plasma drug levels within the predicted therapeutic window. Preclinical studies, presented at the annual International Conference on Antiviral Research in 2024 showed that ratutrelvir demonstrated differentiated activity compared to nirmatrelvir against a range of SARS-CoV-2 variants, based on a comparison of EC50 values.

07:33 EDT BrightSpring Health appoints Steve Miller to board of directors - BrightSpring Health announced that Dr. Steve Miller was appointed as a Class II member of the Board of Directors. Dr. Miller will also serve as a member of the Board's Audit Committee and as the chair of the Board's Quality & Compliance and Governance Committee. Dr. Miller served as the Chief Clinical Officer for Cigna from 2018 to 2022, transitioning to an expert advisor role in 2022 for Cigna's efforts across clinical policy, quality, and performance programs.

07:31 EDT Marimed's Betty's Eddies partners with Keep A Breast Foundation - Betty's Eddies announced its second annual collaboration with the Keep A Breast Foundation to continue advancing breast cancer awareness education and supporting the millions of people affected by the disease. The initiative includes redesigned product packaging and a campaign to foster KAB's mission of reducing breast cancer risk through education, with a focus on early detection. Betty's Eddie's all-natural, cannabis fruit chews, handcrafted to suit a variety of specific effects, is one of the brands produced and distributed by multi-state cannabis operator, MariMed. To commemorate the campaign and raise visibility for KAB's mission, Betty's Eddies will once again launch a limited-time, redesigned pink package for its fan-favorite Ache Away Eddies fruit chews. The packaging, which will be available for a limited time in Massachusetts, Maryland, Illinois, and Delaware, will help promote the KAB app. Available on the Apple and Google Play Stores, it offers education about and advocacy for self-checking and immediately connects users to medical professionals when necessary. The cherry-flavored Ache Away Eddies fruit chew, infused with CBD, CBC, and THC, plus turmeric, piperine, and vitamin E, may help ease inflammation and aid recovery.

07:28 EDT Electrovaya, Innovative Rail Technologies enter supply agreement - Electrovaya announced the establishment of a Strategic Supply Agreement with Innovative Rail Technologies. The Agreement will initially cover the supply of Electrovaya's Infinity battery systems for IRT's electric locomotive systems. IRT is focused on the electrification of locomotives to battery electric through its proprietary advanced technology lithium-ion adaptive system, a turnkey, scalable propulsion and control package customized to the unique needs of customer operations. IRT has a strong pipeline of orders targeting applications in industrial operations, short line railroads, ports, defense and commuter rail.

07:19 EDT Gilat Satellite receives multimillion service contract from satellite operator - Gilat Satellite Networks has secured a Multimillion contract extension to provide services for a leading satellite operator in the Asia-Pacific region for an additional period of 12 months. The extended agreement highlights Gilat's continued support in managing and maintaining the operator's satellite communications infrastructure. Through this contract extension, Gilat will continue to ensure enhanced network performance and reliability for the operator's service coverage.

07:16 EDT Nurix Therapeutics announces presentations at Discovery on Target - Nurix Therapeutics announced three oral presentations at the 22nd Annual Discovery on Target conference, being held September 30 - October 3, 2024, in Boston, MA. Poster Presentation Details: Title: Rational Discovery of a Small Molecule Intramolecular Glue Inhibitor of CBL-B that Enhances T-cell Function: Description: Casitas B lymphoma-b is a RING-type E3 ubiquitin ligase that plays an important role in regulating T cell function. Loss of CBL-B is associated with enhanced T and NK cell activity which makes it an interesting target for immuno-oncology drug development. We present a rational approach to discover and optimize small molecule inhibitors for CBL-B that elicit a potent T cell activation and antitumor activity. Title: The Evolving Chemical Space of Bi-functional Degraders Targeting the CNS: Description: Bi-functional degraders occupy beyond-rule-of-five chemical space where established rules for drug-likeness cannot easily be applied. In contrast to approved CNS drugs, bi-functional degraders violate most metrics, particularly molecular weight, yet we routinely observe brain penetrance in our programs. For example, NX-5948, a clinical stage orally bioavailable BTK degrader shows CNS exposure and activity both preclinically and clinically. This presentation will explore our evolving understanding of targeting the CNS using degraders. Title: Screening DNA Binding Proteins with DNA Encoded Libraries: Description: Transcription factors are historically a challenging target class to drug. Although DNA-encoded libraries have become a staple for ligand discovery, transcription factors and other proteins that specifically bind DNA present distinct challenges for DEL technology. Nurix has developed a broadly applicable approach for applying affinity selection and informatic methods to transcription factors, and these methods have yielded tractable hits for the EWS-FLI1 fusion oncoprotein.

07:13 EDT EchoStar announces suit of transformative transactions - EchoStar Corporation announced a suite of transformative transactions, including: an agreement to sell DISH DBS Corporation to DIRECTV ; the receipt of approximately $2.5 billion in new financing from TPG Angelo Gordon and certain co-investors at DBS to address its November 2024 debt maturity and provide interim liquidity; various exchange offers to DBS bondholders providing the opportunity for its stakeholders to support the combination of the DBS and DIRECTV business and roll into the attractive combined credit; a comprehensive financing solution and balance sheet optimization transaction at EchoStar through

07:11 EDT Prime Medicine unveils strategically focused pipeline - Prime Medicine (PRME) announced that it is focusing its pipeline on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Prime Medicine will focus on the development of two programs for the treatment of chronic granulomatous disease, which together have the potential to address the vast majority of people living with CGD: PM359, an ex vivo autologous hematopoietic stem cell product for the treatment of p47phox CGD; Ex vivo HSC product for the treatment of X-linked CGD. Prime Medicine announced its first follow-on program in hematology and immunology. Building on its efforts in p47phox CGD, Prime Medicine is advancing a program for X-linked CGD, which utilizes its Prime Assisted Site-Specific Integrate Gene Editing technology, and is expected to address over 90 percent of known mutations in the CYBB gene with a single approach. As announced this morning, Prime Medicine entered into a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY). rime Medicine is focused on advancing its Wilson's Disease program, which targets prevalent mutations in the ATP7B gene. Prime Medicine expects to present new preclinical data and initiate IND-enabling activities for this program in the fourth quarter of 2024, and intends to file an IND and/or clinical trial application in the first half of 2026. With funding from the Cystic Fibrosis Foundation, Prime Medicine is continuing to advance two strategies to potentially cure CF: hotspot editing and PASSIGE. Using hotspot editing, the Company aims to address multiple mutations at mutational hotspots with a small number of Prime Editors; using PASSIGE, the Company aims to address nearly all people with CF with a single superexon insertion strategy. In order to pursue its prioritized high value programs as rapidly as possible, the Company is identifying partnership opportunities to advance its other programs, including those for neurological diseases, cell therapy, ocular diseases and hearing loss. Prime Medicine expects that business development will continue to play a critical role in accelerating and funding its pipeline, allowing the Company to maximize the potential and reach of Prime Editing, including in areas outside its core focus. Prime Medicine may also choose to advance these programs through internal efforts in the future. As a result of this strategic pipeline prioritization, Prime Medicine will streamline its operating expenses and capital expenditures. Together with the $110 million upfront consideration received from Bristol Myers Squibb under the strategic research collaboration and license agreement announced this morning, Prime Medicine expects its cash runway to fund operations into the first half of 2026.

07:10 EDT Mercury Systems, Boeing sign contract for FPGA processor boards - Mercury Systems, Inc. (MRCY) signed a contract with Boeing (BA) to deliver FPGA processor boards that will support an upgraded refueling system on the U.S. Air Force's KC-46A tanker aircraft fleet. Mercury's SCFE3920 boards are an integral part of the next-generation KC-46A Remote Vision System 2.0. Designed for high-speed data processing and seamless system integration, Mercury's boards will connect directly to cameras on the plane to process the high-resolution, color video feeds that provide KC-46A operators with a clear and precise view of the refueling process.

07:10 EDT - Precision BioSciences announced that the company submitted Clinical Trial Applications CTA to initiate a Phase 1 study evaluating PBGENE-HBV. PBGENE-HBV is the Companys wholly owned in vivo gene editing program designed to potentially cure chronic hepatitis B virus HBV by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes... Our comprehensive regulatory package, supported by robust non-human primate NHP safety studies, the gold standard model for predicting safety in humans, and efficacy in numerous preclinical models of hepatitis B including in NHPs enables us to proceed with planned regulatory submissions in multiple markets around the world. We recently bolstered our clinical team expertise while building a world class hepatitis scientific advisory board to assist in guiding execution of our global Phase 1 trial. Our goal is clear, to generate robust clinical data for the patients afflicted with hepatitis B who are counting on us to significantly increase their chance of achieving a functional cure. ...Precision is on track to submit additional regulatory applications as part of its global Phase 1 regulatory strategy for PBGENE-HBV. The next update on the PBGENE-HBV program is expected to take place before the American Association for the Study of Liver Diseases AASLD Annual Meeting in November. Details about how to participate in the update will be provided in advance.

07:09 EDT BioCryst awarded $69M RAPIVAB contract by U.S. government - BioCryst Pharmaceuticals announced that the U.S. Department of Health and Human Services has awarded BioCryst up to a $69 million contract for the procurement of up to 95,625 doses over a five-year period of RAPIVAB for the treatment of influenza. The contract, awarded by the HHS Office of the Administration for Strategic Preparedness and Response, will supply the Center for the Strategic National Stockpile, the nation's largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency. The contract is structured with a 12-month base ordering period and four optional 12-month ordering periods, which the government can exercise on an annual basis. ASPR has executed the first ordering period for $13.9 million and BioCryst plans to supply 19,125 doses to fulfill this option between now and September 29, 2025.

07:08 EDT Prime Medicine announces collaboration, license agreement with Bristol Myers - Prime Medicine (PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY) to develop reagents for the next generation of ex vivo T-cell therapies. Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing technology. Bristol Myers Squibb will be responsible for development, manufacturing and commercialization of the next generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development. "We are excited to collaborate with Bristol Myers Squibb, a global leader in cell therapy for hematology, immunology, and oncology. Through this effort, we will apply our Prime Editing technology beyond the rare genetic diseases in our internal pipeline, potentially unlocking opportunities in areas of high unmet needs in immunological diseases and cancer," said Keith Gottesdiener, M.D., President and CEO of Prime Medicine. Under the terms of the agreement, Prime Medicine will receive a $55M upfront payment and a $55M equity investment from Bristol Myers Squibb. Prime Medicine is also eligible to receive more than $3.5B in milestones, including up to $1.4 billion in development milestones and more than $2.1B in commercialization milestones, along with royalties on net sales.

07:07 EDT NRx Pharmaceuticals announces completion of 12 months of stability of NRX-100 - NRx Pharmaceuticals announced that twelve-month real-time stability on the first manufactured lot of NRX-100 at Nephron Pharmaceuticals, utilizing commercial scale processes, was reached on September 24, 2024. In this process, no degradation of the active ingredient was observed. These findings are consistent with projected room temperature shelf stability in excess of three years. Accelerated stability on additional manufactured lots of preservative-free product is congruent with stability seen in this initial lot. Demonstrating the ability to manufacture drug product, and prove its stability, are critical components of the drug approval process with the US FDA. Filing of the NDA for NRX-100 is on track for 2024. The NRX-100 formulation is the first sterile, single dose vial prepared with without the addition of preservatives, which may have toxic effects with repeated use.

07:04 EDT Gogo to acquire Satcom Direct for $375M in cash, 5M shares - Gogo and Satcom Direct announced entry into a definitive agreement under which Gogo will acquire Satcom Direct to create the only in-flight connectivity provider able to satisfy the performance and cost needs of every segment of the global business aviation and military/government mobility markets. Under the terms of the agreement, Satcom Direct will receive $375 million in cash and five million shares of Gogo stock at closing, and up to an additional $225 million in payments tied to realizing certain performance thresholds over the next four years.

07:03 EDT Adicet Bio opens enrollment for ADI-001 - Adicet Bio announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. This announcement follows the FDA decision to grant Fast Track Designation to ADI-001 for the treatment of relapsed/refractory class III or class IV LN and clearance from the FDA to develop ADI-001 in four autoimmune indications, including LN, SLE, SSc, and AAV. The Phase 1 study has three separate arms, enrolling LN and SLE patients into one arm, SSc patients into a second arm and AAV patients into a third arm. Enrolled patients will receive a single dose of ADI-001. The dose-limiting toxicity window is 28 days with response and safety assessments conducted on Day 28 and during the follow up period on months 3, 6, 9, 12, 18 and 24. The primary objectives of the study are to evaluate the safety and tolerability of ADI-001. Secondary objectives include measuring cellular kinetics, pharmacodynamics, changes in autoantibody titers, and appropriate disease activity scores in each indication.

07:00 EDT Site Centers provides transaction, Curbline balance sheet - SITE Centers provided an update on transaction activity along with updated projected Curbline Properties balance sheet information. From September 17, 2024 to September 27, 2024, SITE Centers sold 11 wholly owned properties for an aggregate gross price of $610.1 million. As a result of disposition activity, Curbline is now expected to be capitalized with $800 million of cash at the time of the spin-off in addition to a $400 million undrawn, unsecured line of credit, a $100 million unsecured, delayed draw term loan and no indebtedness. As previously announced, the distribution of the shares of Curbline common stock is expected to be completed at 12:01 a.m. Eastern Time on October 1, 2024. Following such distribution, Curbline will be an independent, publicly traded company listed on the New York Stock Exchange under the ticker symbol "CURB". SITE Centers shareholders will receive two shares of Curbline common stock for every one common share of SITE Centers held at the close of business on the record date of September 23, 2024.

06:58 EDT Aecom names Jill Hudkins chief executive, Water & Environment Advisory line - AECOM has appointed Jill Hudkins as chief executive of its new Water & Environment Advisory global business line. The appointment of Ms. Hudkins and the formation of the new advisory business mark key milestones in the Company's growth strategy, which is built on extending AECOM's competitive advantage by drawing on its technical leadership and strong client relationships to develop complementary, high-value businesses. The Water & Environment Advisory global business line will focus on advising clients to strategically guide them through the lifecycle of their largest and most complex water and environmental management challenges. Leveraging AECOM's existing number one water, environmental engineering and environmental science businesses, as ranked by Engineering-News Record, the new advisory business will expand the Company's capabilities in high growth areas, such as advanced digital water asset management and automation, environmental permitting, per- and polyfluoroalkyl substances remediation and emerging opportunities for water solutions in high-tech environments. Hudkins previously served as President at Tetra Tech with more than 25 years of experience spanning several operational and strategic leadership roles at the firm

06:55 EDT West Red Lake acknowledges Truth and Reconciliation Day - West Red Lake Gold Mines acknowledges those who were lost and those who survived residential schools, as well as their families and communities. Through implementing the Truth and Reconciliation Corporate Calls to Action, the Company is striving to be a leader in economic reconciliation. "Actively working to see the truth of Canada's treatment of First Nations and finding ways to reconcile and heal are essential and we keenly embrace the Corporate Calls to Action at West Red Lake Gold," said Shane Williams, President and CEO. "While we wear orange as protective, reflective gear every day, the Orange T-Shirt is impactful to the WRLG team in how it grew out of a youth led, grass roots movement to illustrate the resilience of the survivors of residential schools, who had to fight the stripping away of culture, freedom and self-esteem." The Company's Madsen Mine and Rowan projects are within Treaty #3 and the traditional territories of Lac Seul and Wabauskang First Nation, with whom West Red Lake Gold has a Project Partnership Agreement in place to guide relations.

06:48 EDT TE Connectivity completes incorporation change - TE Connectivity completed the change in the place of incorporation of the publicly traded parent company of TE Connectivity from Switzerland to Ireland. The change in place of incorporation resulted in each shareholder of TE Connectivity receiving one share of TE Connectivity plc, a company incorporated under the laws of Ireland, for each share of TE Connectivity held immediately prior to the change in incorporation. The company will continue to be a U.S. Securities and Exchange Commission reporting company and its ordinary shares will continue to trade on the New York Stock Exchange under the symbol TEL.

06:46 EDT Diversified Healthcare Trust enter purchase, sale agreement with Brookdale - Diversified Healthcare Trust (DHC) has entered into a purchase and sale agreement with Brookdale Senior Living Inc. (BKD) whereby Brookdale will acquire 18 triple net leased senior living communities that Brookdale currently leases from DHC for $135 million. Brookdale has leased and operated these 18 communities since February 2003. The 18 communities include 876 units located across 10 states serving primarily assisted living residents as well as memory care residents. DHC intends to use the proceeds from the transaction to pay down its $941 million of senior secured notes due January 2026.The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.

06:41 EDT Wesdome Gold Mines appoints Guy Belleau as COO - Wesdome Gold Mines announces the appointment of Mr. Guy Belleau as COO. Belleau is a Professional Engineer who has spent more than three decades in mine operations, development, and management. Most recently, he served as CEO of Sayona Canada, a subsidiary of Australian-listed Sayona Mining.

06:39 EDT NanoViricides says made 'significant progress' in NV-387 regulatory advancement - The company said, "We have made significant progress in the regulatory advancement of NV-387. A Phase Ia/Ib clinical trial in healthy subjects was completed with all subjects discharged as of end of December, 2023. There were no adverse events reported. Lab data analysis is currently being conducted. We are awaiting a final report. Additionally, we have made significant progress in expanding the indications of NV-387, that would result in substantial improvement in the return on investment when regulatory approvals are obtained. Our host-mimetic, direct-acting, broad-spectrum, antiviral agent. NV-387 was found to have activity that surpassed the activity of known agents in lethal virus infection animal model trials for COVID, RSV, and Influenza. In fact, we found that NV-387 treatment possibly completely cured the lethal RSV infection in mice, based on indefinite survival of the animals with no lung pathology. There is currently no treatment for RSV infection. In particular, pediatric RSV infection treatment is an unmet medical need that we believe is of critical importance. Pediatric RSV treatment itself is expected to be a multi-billion-dollar market in the USA alone. NV-387 treatment was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir, peramivir, and baloxavir. Additionally, NV-387 also demonstrated activity against lethal poxvirus infection animal models that was on par with the approved drug tecovirimat. NV-387 acts by a mechanism that is significantly different compared to the tested existing antiviral agents for Influenza and for Poxviruses. This demonstrated broad-spectrum activity of NV-387 against widely varying viruses is because NV-387 is designed to attack the virus particle by mimicking sulfated proteoglycan feature, and all of these viruses are known to utilize heparan sulfate proteoglycans for gaining cell entry. Further, for all of these tested viruses, even as the virus genome changes in the field, NV-387 is expected to continue to be effective, and the virus would be highly unlikely to escape NV-387. This is because despite all of the genomic changes, the virus continues to use HSPG, as is well known. Thus NV-387 solves the greatest problem in antiviral countermeasures; the problem of virus escape. Viruses are known to escape all of the current antiviral tools that include vaccines, antibodies, and small chemical drugs. Thus we anticipate that NV-387 would revolutionize the treatment of viral infections reminiscent of how penicillin revolutionized the treatment of bacterial infections."

06:35 EDT KalVista submits additional MAAs for sebetralstat for treatment of HAE - KalVista announced Marketing Authorization Application submissions to the regulatory authorities in the United Kingdom, Switzerland, Australia, and Singapore for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema attacks in adults and adolescents aged 12 years and older. The four MAAs have been submitted via the Access Consortium framework for which KalVista has obtained a four-way work-sharing agreement by the Medicines and Healthcare product Regulatory Agency, Swissmedic, the Therapeutic Goods Administration and Health Sciences Authority. The Access Consortium is designed to maximize regulatory collaboration across countries and support a timely review process. The MAA submissions are supported by previously disclosed results, including data from the KONFIDENT phase 3 clinical trial and ongoing KONFIDENT-S open label extension trial. Sebetralstat met the primary endpoint for its phase 3 trial with both 300 mg and 600 mg formulations achieving the beginning of symptom relief significantly faster than placebo and was well-tolerated, with a safety profile similar to placebo. In KONFIDENT-S, sebetralstat has enabled patients to treat attacks early with a median time from attack onset to treatment of 9 minutes, demonstrated a consistent safety and efficacy profile with KONFIDENT, and included a median time to beginning of symptom relief for laryngeal attacks of 1.3 hours. KONFIDENT and KONFIDENT-S are the only clinical trials ever conducted in HAE that instruct participants to treat their attacks as early as possible, regardless of severity, in accordance with on-demand treatment guidelines. Early treatment of attacks, prior to progression, is a critical element in proper management of HAE, to minimize symptom burden. KalVista's KONFIDENT-KID clinical trial, designed to evaluate the safety and efficacy of sebetralstat in a pediatric population aged 2-11 years, began dosing patients ahead of schedule in June 2024.

06:33 EDT AT&T to sell remaining 70% stake in DIRECTV to TPG - AT&T (T) reached an agreement to sell its remaining stake in DIRECTV to TPG (TPG). Under the agreement, the company will sell its entire 70% stake in a non-contingent transaction subject only to customary closing conditions. Over the past three years, the company achieved financial outcomes consistent with its expectations that underpinned its decision to retain a 70% financial interest in DIRECTV. Reported cash distributions at, and since, the closing of its initial transaction with TPG totaled $19B and the company expects to report an additional $7.6B of cash payments following this agreement to sell its remaining stake. The company expects the transaction to close in the second half of 2025.

06:27 EDT Baxter says North Cove, NC facility affected by Hurricane Helene - Baxter shared updates regarding the impact of Hurricane Helene, which brought unprecedented rain and extensive flooding to Western North Carolina, on the operations of its North Cove facility in Marion, N.C. Baxter's North Cove site was affected by flooding due to the storm and is currently closed for production. The company is working around the clock in close coordination with local, state and federal officials to assess the extent of the damage and implement a plan to bring the plant back online as quickly as possible to help mitigate supply disruption to patients. Ahead of the storm, Baxter implemented its hurricane preparedness plan, which included evacuation plans for colleagues, as well as proactively moving products to higher ground or secure storage where feasible. The heavy rain and storm surge triggered a levee breach, which led to water permeating the site. The bridges accessing the site have also been damaged. Baxter is communicating with its customers about the actions the company is taking to minimize potential disruptions. These include actively managing inventory and implementing a protective allocation process by product line to help support supply continuity and equitable product distribution. The company will leverage Baxter's global manufacturing network to help mitigate potential supply impact as it continues efforts to fully restore North Cove's manufacturing operations. Baxter will continue to provide updates as additional information becomes available and aims to provide an update on estimated timing to resume production as soon as it is able. While the company is working expeditiously to restore its manufacturing operations and return to production, the disruption is anticipated to negatively impact the company's financial results. Once the company can more fully assess the damage, it will be in a better position to estimate any expected impact and plans to provide an update in its third quarter earnings announcement.

06:21 EDT Leapmotor International opens orders in Europe for T03, C10 vehicles - Designated Stellantis brand vehicle dealers throughout Europe are now taking orders for Leapmotor fully electric vehicles, with deliveries set for later this year. The launch of dealer orders is a milestone for Leapmotor International, the 51:49 joint venture between Stellantis and Leapmotor. The milestone was achieved in just under one year since the joint venture was formed, concurrent with Stellantis investing EUR 1.5G to acquire approximately 21% of Leapmotor. Initial markets for Leapmotor vehicles in Europe will be Belgium, France, Germany, Greece, Italy, Luxemburg, Malta, The Netherlands, Portugal, Romania, Spain, Switzerland, and the UK. Leapmotor International plans to expand distribution to Middle East & Africa, Asia Pacific, and South America from Q4 this year. Leapmotor launches with two fully equipped models in Europe: The T03, a 5-door A-segment compact car with 265 km of range and the interior space of a B-segment. T03 will be offered starting from 18.900 euros available now. The C10, a D-segment SUV with 420 km of range and best-in-class safety, an intelligent user experience, and premium levels of comfort. It uses Leapmotor's LEAP 3.0 architecture with a centrally integrated electronic configuration, the Cell-to-Chassis system, and a smart cockpit. C10 SUV will be available from 36.400 euros and planned to arrive at respective dealerships in-October.

06:18 EDT reAlpha invests in Xmore AI, terms not disclosed - reAlpha Tech announced the selection of Xmore AI as the first company to secure investment from its newly launched reAlpha AI Labs, reAlpha's research and development initiative. Xmore AI, co-founded by Dr. Benjamin Yan and Adrian Self, leverages over a decade of research in AI-driven cybersecurity and has developed a platform that consolidates multiple cybersecurity tools into a seamless, AI-driven solution, ensuring that enterprises can operate securely in a rapidly evolving digital environment. Dr. Yan is a Professor of Computer Science and Engineering at Michigan State University. Adrian Self, a cybersecurity professional with extensive experience in blockchain security and embedded systems, complements Dr. Yan's expertise with his hands-on approach to security assessments and technology integration. This investment marks a strategic milestone for reAlpha AI Labs to accelerate the development of AI technologies and advance technology innovation in the real estate industry. In addition to enhancing reAlpha's AI homebuying platform through its AI-cybersecurity expertise, Xmore AI is developing a software that will consolidate multiple cybersecurity tools to provide AI-cybersecurity solutions to enterprises in multiple industries. At the core of Xmore AI's innovation is its ability to address the unique vulnerabilities created by the rapid expansion of AI across industries. We believe Xmore AI is well-positioned to address critical challenges like data privacy, compliance, and risk management, by providing innovative solutions designed to meet the evolving needs of the cybersecurity landscape.

06:17 EDT Brookdale Senior Living to acquire 41 leased communities, sees accretion - Brookdale Senior Living (BKD) announced that in a financing led by Deerfield Management, the company is addressing 83% of all 2026 debt maturities and is securing capital to support immediately accretive acquisition opportunities. The company also announced the successful refinancing of its 2025 agency debt maturity at a favorable rate. The company has entered into definitive agreements to acquire three portfolios of senior living communities that are currently leased by the Company. Through ownership of these communities, the company will gain portfolio management flexibility that is not present in a leased structure, providing additional opportunities to further enhance shareholder value. These transactions are expected to close by year-end, subject to the satisfaction of customary closing conditions for real estate transactions. The company has entered into a definitive agreement to acquire 11 senior living communities from a joint venture between Welltower and its joint venture partners for a purchase price of $300M. As part of this transaction, the company will assume $195M of existing 4.92% fixed rate agency debt which is scheduled to mature in March 2027. Currently, these communities are held in a triple-net lease with annualized current cash rent payments of $22M and a current maturity of August 31, 2028. This portfolio of communities is largely on the west coast, including several communities in and around Seattle as well as a Bay Area community. The portfolio is comprised of 470 independent living units, 723 assisted living units, and 36 memory care units with weighted average portfolio occupancy of approximately 80%. In 2019, these communities operated at a weighted average occupancy of 88%, reflecting an opportunity to enhance long-term value creation for the benefit of the Company and its shareholders. The company has entered into a definitive agreement to acquire five senior living communities from Welltower for a purchase price of $175M. Currently, these communities are held in a triple-net lease with annualized current cash rent payments of $13M and a current maturity of December 31. This portfolio of communities is largely located in affluent markets, including Nashville, Overland Park and Denver. In total, the portfolio is comprised of 270 independent living units, 170 assisted living units, 152 memory care units, and 94 skilled nursing units with weighted average portfolio occupancy greater than 90%. The acquisition purchase price, including the benefit of a favorable purchase option discount, also reflects a significant discount to the company's estimate of replacement cost. The company has entered into a definitive agreement to acquire 25 senior living communities from Diversified Healthcare Trust (DHC) for a purchase price of $135M. Currently, these communities are held in a triple-net lease with annualized current cash rent payments of $10M and a current maturity of December 31, 2032. This portfolio's communities are diversely located, range in size from 19 units to 92 units, and include a total of 556 assisted living units and 319 memory care units with weighted average portfolio occupancy of approximately 80%.

06:13 EDT Klotho Neurosciences appoints Robert Langer to Scientific Advisory Board - Klotho Neurosciences (KLTO) announced that Dr. Robert Langer, co-founder of Moderna (MRNA), has joined its Scientific Advisory Board. In addition to lending his scientific expertise to guide the company's strategic direction, this also signals Dr. Langer's strong belief in the company's mission and potential. He is a Professor at the Massachusetts Institute of Technology and a faculty member of the Harvard-MIT Program in Health Sciences and Technology.

06:11 EDT Emeren sells 57 MWp solar project portfolio to Trina Solar Systems - Emeren announced the sale of a 57 MWp solar project portfolio to Trina Solar Systems, the French subsidiary of Trina Solar International System Business Unit, or ISBU, the downstream project development arm of Trina Solar dedicated to the development, EPC, O&M, and asset management of solar and battery storage utility-scale projects worldwide. The portfolio includes five projects - one early-stage and one late-stage - both sold in Q3 2024, along with three mid-stage projects to be monetized in milestones and sold to Trina. Additionally, there is potential to incorporate Battery Energy Storage Systems, which could further increase the portfolio's flexibility and overall value.

06:08 EDT Iveco Group receives three contracts for electric mobility solutions in France - IVECO BUS received three new contracts for electric mobility solutions in France, reinforcing the brand's leadership in the transition to cleaner, greener public transport. In total, 31 hydrogen fuel cell buses and 20 battery electric buses have been ordered since the beginning of September. Cannes Lerins Urban Community has renewed its trust in IVECO BUS and ordered twelve GX 337 H2 LINIUM BRT hydrogen fuel cell buses. Deliveries will start in the second half of 2025 to complement the thirty-five IVECO BUS GX ELEC battery electric buses already in the fleet. Lorient Agglomeration has also chosen IVECO BUS's hydrogen technology for its network, with nineteen GX 337 H2 LINIUM buses, five of which will enter service in the second half of 2025. The third contract is with Grand Reims Mobilites which has selected IVECO BUS to deliver twenty GX 437 ELEC LINIUM BRT battery electric buses. These vehicles will begin operating on the streets of Reims in autumn 2025.

06:06 EDT CuriosityStream announces collaboration with Shell Recharge - Shell Recharge (SHEL) and Curiosity (CURI) are teaming up to help drivers stay engaged, educated, and entertained while they 'charge smart.' The campaign kicks off from October 1st to November 24th, 2024, in the Netherlands. Shell Recharge is giving its app users in The Netherlands free access to Curiosity Stream. Courtesy of Shell, Recharge app users will have immediate access to Curiosity Stream's deep library of films and series exploring science, nature, history, technology, and more. Consumers can log in to watch thousands of shows making the EV experience even more enjoyable. Using the Shell Recharge app, drivers can find, access, and pay at more than 500 public charging points across the Netherlands. Using the navigator features, drivers can simply locate stations, filter the type of charger, connector type, and power. But the experience doesn't end there. On the Recharge app, drivers can find complimentary access to Curiosity Stream to dive in and stream smart while they charge smart.

06:02 EDT AudioEye acquires ADA Site Compliance, terms undisclosed - AudioEye announced it has acquired ADA Site Compliance, an ADA website accessibility compliance solution that provides audits and best practices to help organizations create websites that are accessible and compliant to WCAG standards. The acquisition of ADA Site Compliance is expected to be accretive in the fourth quarter.

05:30 EDT Payfare initiates strategic review - Payfare announced that its board of directors has initiated, with the assistance of outside legal and financial advisors, a strategic review process to explore and evaluate a broad range of potential options for the company to enhance value. The foundation, funding, and execution of Payfare's ongoing programs remain secure with a robust pipeline of potential new opportunities in the gig economy and EWA space. To support conversion of these new opportunities and alleviate concentration risk, the board has decided to initiate a strategic review to accelerate these goals. During this process, Payfare remains focused on executing its current business strategy and will continue to provide financial solutions for its clients and cardholders. This review process will assess strategic alternatives that may include, but are not limited to strategic partnerships, strategic investments, accretive acquisitions, a potential sale, merger or other business combination. In conducting the strategic review, the company's board and management team are committed to acting in the best interests of the company, its shareholders and its stakeholders. There is no deadline or definitive timetable for the completion of the strategic review and Payfare does not intend to comment further unless the board has approved a specific transaction or otherwise determined that disclosure is necessary or appropriate. There can be no assurances that the strategic review will result in any specific transaction or outcome.

05:18 EDT Stellantis raises FY24 industrial free cash flow view to EUR 5B-EUR 10B - Raises FY24 operating income margin view to 5.5%-7%. Stellantis revised its 2024 financial guidance, reflecting decisions to significantly enlarge remediation actions on North American performance issues, as well as deterioration in global industry dynamics. The company has accelerated its planned normalization of inventory levels in the U.S., targeting no more than 330,000 units of dealer inventory by year-end 2024, from a prior timing objective of the first quarter of 2025. Actions include North American shipment declines of more than 200,000 vehicles in the second half of 2024, compared to the prior year period, increased incentives on 2024 and older model year vehicles, and productivity improvement initiatives that encompass both cost and capacity adjustments. Deterioration in the global industry backdrop reflects a lower 2024 market forecast than at the beginning of the period, while competitive dynamics have intensified due to both rising industry supply, as well as increased Chinese competition. The company's updated 2024 market outlook and financial guidance is as follows: adjusted operating income margin - expected to be between 5.5%-7% for the FY24 period, down from prior "double digit". Roughly two-thirds of the reduced AOI margin is driven by corrective actions in North America. Other contributors include lower than expected sales performance in the second half of the year across most regions. Industrial free cash flow - expected to range from -EUR 5B to EUR 10B, from prior "positive". This primarily reflects the substantially lower AOI outlook as well as the impact of temporarily elevated working capital in the second half of 2024.

05:03 EDT Yunji regains compliance with Nasdaq - Yunji announced that it received a notification letter from Nasdaq Stock Market indicating that the company has regained compliance with the Nasdaq Listing Rule 5450(a)(2) and the matter is closed.